MSS7MarcSabatineMarc Steven Sabatine, M.D.42.33510370000000-71.106164900000001849Sabatine, MarcSteven617/278-0145Professor of Medicinecatalyst:eCommonsLogineCommons Loginprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 10454071929406853Bansilal S, Bonaca MP, Cornel JH, Storey RF, Bhatt DL, Steg PG, Im K, Murphy SA, Angiolillo DJ, Kiss RG, Parkhomenko AN, Lopez-Sendon J, Isaza D, Goudev A, Kontny F, Held P, Jensen EC, Braunwald E, Sabatine MS, Oude Ophuis AJJournal of the American College of CardiologyTicagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. J Am Coll Cardiol. 2018 02 06; 71(5):489-496.J Am Coll Cardiol2018-02-06T00:00:002018Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.Authorship 10519175Authorship 10531601Authorship 10527771329530884Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MSCirculationInflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018 07 10; 138(2):131-140.Circulation2018-03-12T00:00:002018Inflammatory and Cholesterol Risk in the FOURIER Trial.29525817Sabatine MSJAMA cardiologyPharmacogenetics and the Promise of Personalized Medicine. JAMA Cardiol. 2018 05 01; 3(5):408.JAMA Cardiol2018-05-01T00:00:002018Pharmacogenetics and the Promise of Personalized Medicine.29536853Giugliano RP, Keech AC, Sever PS, Pedersen TR, Sabatine MSLancet (London, England)Clinical benefits of evolocumab appear less than hoped - Authors' reply. Lancet. 2018 03 10; 391(10124):934-935.Lancet2018-03-10T00:00:002018Clinical benefits of evolocumab appear less than hoped - Authors' reply.Bonaca MP, Morrow DA, Wiviott SD, Sabatine MS, Murphy SA, Scirica BM, Rifai N, Antman EM, Braunwald E.CirculationClinical correlates and impact of aspirin on the inflammatory response to percutaneous coronary intervention: Results from TIMI 26. Circulation. 2005; 112(Suppl II):II-694.2005-11-08T00:00:002005Clinical correlates and impact of aspirin on the inflammatory response to percutaneous coronary intervention: Results from TIMI 2619237657Cheng S, Morrow DA, Sloan S, Antman EM, Sabatine MSCirculationPredictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation. 2009 Mar 10; 119(9):1195-202.Circulation2009-02-23T00:00:002009Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.16537575O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald ECirculationLipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11; 113(14):1745-52.Circulation2006-03-14T00:00:002006Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.19372185Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SAClinical chemistryDeveloping multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem. 2009 Jun; 55(6):1108-17.Clin Chem2009-04-16T00:00:002009Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry.Johannsen EC, Sabatine MSPharmCardsPharmCards. 1995.1995-01-01T00:00:001995PharmCardsBonaca, MP, Morrow DA, Sabatine MS, Ray KK, Rifai, N, Cannon CP.Circulation.Elevated levels of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in PROVE-IT TIMI 22. Circulation. 2006; 114(Suppl II):II-649.2006-01-01T00:00:002006Elevated levels of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in PROVE-IT TIMI 22Sabatine MS, Jang I-KCannon CP, ed. The Management of Acute Coronary Syndromes.Antiplatelet and antithrombotic therapy. Cannon CP, ed. The Management of Acute Coronary Syndromes. 1998; 293-336.1998-01-05T00:00:001998Antiplatelet and antithrombotic therapySabatine MS, Antman EM, Ganz LI, Strichartz GR, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Mechanisms of cardiac arrhythmias. Lilly LS, ed. Pathophysiology of Heart Disease. 1998; 233-48.1998-01-03T00:00:001998Mechanisms of cardiac arrhythmiasSabatine MS, Antman EM.Use of abciximab in unstable angina/Non ST elevation myocardial infarction: The GUSTO IV ACS trial.Use of abciximab in unstable angina/Non ST elevation myocardial infarction: The GUSTO IV ACS trial. 2001.2001-01-01T00:00:002001Use of abciximab in unstable angina/Non ST elevation myocardial infarction: The GUSTO IV ACS trial18435949Gibson CM, Pride YB, Buros JL, Kunadian V, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Braunwald EThe American journal of cardiologyRelation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy. Am J Cardiol. 2008 May 01; 101(9):1232-8.Am J Cardiol2008-03-05T00:00:002008Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy.19332591Bhatt DL, Kottke-Marchant K, Alexander JH, Peacock WF, Sabatine MSCleveland Clinic journal of medicinePlatelet response in practice: Applying new insights and tools for testing and treatment. Cleve Clin J Med. 2009 Apr; 76 Suppl 1:S24-32.Cleve Clin J Med2009-04-01T00:00:002009Platelet response in practice: Applying new insights and tools for testing and treatment.15824203Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald ECirculationAssociation of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005 Apr 26; 111(16):2042-9.Circulation2005-04-11T00:00:002005Association of hemoglobin levels with clinical outcomes in acute coronary syndromes.16368287Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CPAmerican heart journalCombination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006 Jan; 151(1):25-31.Am Heart J2006-01-01T00:00:002006Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction.19168551Gerszten RE, Sabatine M, Wang TJClinical chemistryNew antibody assays for cardiovascular disease: future tools for the clinical chemist? Clin Chem. 2009 Mar; 55(3):404-6.Clin Chem2009-01-23T00:00:002009New antibody assays for cardiovascular disease: future tools for the clinical chemist?19726078O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SDLancet (London, England)Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-997.Lancet2009-08-31T00:00:002009Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.20215905Gibler KB, Huskamp HA, Sabatine MS, Murphy SA, Cohen DJ, Cannon CPCritical pathways in cardiologyCost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction. Crit Pathw Cardiol. 2010 Mar; 9(1):14-8.Crit Pathw Cardiol2010-03-01T00:00:002010Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction.22179538Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, Solomon SD, Pfeffer MA, Braunwald ECirculationEvaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012 Jan 17; 125(2):233-40.Circulation2011-12-16T00:00:002011Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.22381424Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS, Dauerman HL, French PA, Becker RCJournal of the American College of CardiologyPlatelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol. 2012 Mar 06; 59(10):891-900.J Am Coll Cardiol2012-03-06T00:00:002012Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease.22901500Braunwald E, Sabatine MSThe Journal of thoracic and cardiovascular surgeryThe Thrombolysis in Myocardial Infarction (TIMI) Study Group experience. J Thorac Cardiovasc Surg. 2012 Oct; 144(4):762-70.J Thorac Cardiovasc Surg2012-08-15T00:00:002012The Thrombolysis in Myocardial Infarction (TIMI) Study Group experience.Wiviott SD, Morrow DA, Sabatine MS, Murphy SA, Winters KJ, Antman EM, Braunwald E.CirculationPrasugrel suppresses the early rise of sCD40 ligand levels following PCI compared to clopidogrel: A JUMBO - TIMI 26 Substudy. Circulation. 2005; 112(Suppl II):II-432.2005-11-01T00:00:002005Prasugrel suppresses the early rise of sCD40 ligand levels following PCI compared to clopidogrel: A JUMBO - TIMI 26 SubstudyAuthorship 10621011329710336Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue MLJAMA cardiologyAssociation of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 06 01; 3(6):473-480.JAMA Cardiol2018-06-01T00:00:002018Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.de Lemos JA, Morrow DA, Wiviott SD, Jarolim P, Blazing MA, Shiu A, Sabatine MS, Califf RM, Braunwald E.Circulation.Evaluation of monocyte chemoattractant protein 1 as a prognostic marker in the A to Z trial. Circulation. 2006; 114(Suppl II):II-648.2006-01-01T00:00:002006Evaluation of monocyte chemoattractant protein 1 as a prognostic marker in the A to Z trialSabatine MS, editor.Pocket MedicinePocket Medicine. 2007.2007-08-01T00:00:002007Pocket MedicineGupta A, Sabatine MS, O'Gara PT, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Acute coronary syndromes. Lilly LS, ed. Pathophysiology of Heart Disease. 2003; 157-84.2003-01-02T00:00:002003Acute coronary syndromes16520416Armstrong EJ, Morrow DA, Sabatine MSCirculationInflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation. Circulation. 2006 Mar 07; 113(9):e382-5.Circulation2006-03-07T00:00:002006Inflammatory biomarkers in acute coronary syndromes: part IV: matrix metalloproteinases and biomarkers of platelet activation.Authorship 1038102Authorship 1065655229768954Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JPJournal of cardiovascular pharmacology and therapeuticsComparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. J Cardiovasc Pharmacol Ther. 2018 09; 23(5):423-432.J Cardiovasc Pharmacol Ther2018-05-16T00:00:002018Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.Authorship 1067534129626068Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TRCirculationClinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. Circulation. 2018 08 21; 138(8):756-766.Circulation2018-08-21T00:00:002018Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.22412092Panagia M, Winston B, Click JW, Sabatine MS, Resnic FSCirculationA rare complication of infective endocarditis. Circulation. 2012 Mar 13; 125(10):1316-7.Circulation2012-03-13T00:00:002012A rare complication of infective endocarditis.Authorship 10697141429803985Bohula EA, Scirica BM, Fanola C, Inzucchi SE, Keech A, McGuire DK, Smith SR, Abrahamsen T, Francis BH, Miao W, Perdomo CA, Satlin A, Wiviott SD, Sabatine MSAmerican heart journalDesign and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Am Heart J. 2018 08; 202:39-48.Am Heart J2018-03-29T00:00:002018Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.16352794Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald EJAMAPrognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005 Dec 14; 294(22):2866-71.JAMA2005-12-14T00:00:002005Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.16442899Januzzi JL, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald EAmerican heart journalPredicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb; 151(2):360-6.Am Heart J2006-02-01T00:00:002006Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies.18222355Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, Simonsen KL, Kirchgessner TG, Cannon CP, Devlin JJ, Braunwald EJournal of the American College of CardiologyPolymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2008 Jan 29; 51(4):449-55.J Am Coll Cardiol2008-01-29T00:00:002008Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.10902044Gimelli G, Kalra A, Sabatine MS, Jang IKActa cardiologicaPrimary versus rescue percutaneous coronary intervention in patients with acute myocardial infarction. Acta Cardiol. 2000 Jun; 55(3):187-92.Acta Cardiol2000-06-01T00:00:002000Primary versus rescue percutaneous coronary intervention in patients with acute myocardial infarction.11733390Sabatine MS, Braunwald ECirculationWill diabetes save the platelet blockers? Circulation. 2001 Dec 04; 104(23):2759-61.Circulation2001-12-04T00:00:002001Will diabetes save the platelet blockers?12586266Januzzi JL, Sabatine MS, Wan Y, Servoss SJ, DiBattiste PM, Jang Ik, Theroux PThe American journal of cardiologyInteractions between age, outcome of acute coronary syndromes, and tirofiban therapy. Am J Cardiol. 2003 Feb 15; 91(4):457-61.Am J Cardiol2003-02-15T00:00:002003Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.Authorship 107553716Authorship 107227314Authorship 10726761129898218Martin SS, Giugliano RP, Murphy SA, Wasserman SM, Stein EA, Ceška R, López-Miranda J, Georgiev B, Lorenzatti AJ, Tikkanen MJ, Sever PS, Keech AC, Pedersen TR, Sabatine MSJAMA cardiologyComparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018 08 01; 3(8):749-753.JAMA Cardiol2018-08-01T00:00:002018Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial.29898853Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MSAmerican heart journalThe design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018 06; 200:83-89.Am Heart J2018-02-07T00:00:002018The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.29895599Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C, Nicolau JC, Henry P, Kedev S, Wiviott SD, Sabatine MS, Mehta SR, Steg PGCirculation. Cardiovascular interventionsActivated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial. Circ Cardiovasc Interv. 2018 06; 11(6):e006084.Circ Cardiovasc Interv2018-06-01T00:00:002018Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment-Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors: Impact on Ischemic and Bleeding Outcomes: Insights From the TAO Trial.Kirtane AJ, Sabatine MS, Aroesty JM, Murphy SA, Scirica BM, Pinto DS, Southard M, Stein E, Cannon CP, Braunwald E, Gibson CM.CirculationDifferences between Streptokinase and Fibrin-Specific Fibrinolytic Therapy When Co-Administered with Adjunctive Clopidogrel: A CLARITY-TIMI 28 Substudy. Circulation. 2005; 112(Suppl II):II-567.2005-11-05T00:00:002005Differences between Streptokinase and Fibrin-Specific Fibrinolytic Therapy When Co-Administered with Adjunctive Clopidogrel: A CLARITY-TIMI 28 SubstudySabatine MS, Morrow DA, O'Donoghue M, Jablonski KA, Rice MM, Solomon SD, Rosenberg YD, Domanski MJ, Hsia J.Circulation.Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Is an Independent Predictor of Adverse Cardiovascular Outcomes in Patients with Stable Coronary Artery Disease. Circulation. 2006; 114(Suppl II):II-713.2006-01-01T00:00:002006Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Is an Independent Predictor of Adverse Cardiovascular Outcomes in Patients with Stable Coronary Artery DiseaseAuthorship 1173542Authorship 113732521884870Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM, O'Donoghue ML, Bernlochner I, Contant CF, Guo J, Sabatine MS, Schömig A, Neumann FJ, Kastrati A, Wiviott SD, Sibbing DAmerican heart journalImpact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J. 2011 Sep; 162(3):518-26.e5.Am Heart J2011-08-11T00:00:002011Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.14551514Chen AA, Sabatine MSMinerva cardioangiologicaThe management of unstable angina and non-ST-segment elevation myocardial infartion. Minerva Cardioangiol. 2003 Oct; 51(5):433-45.Minerva Cardioangiol2003-10-01T00:00:002003The management of unstable angina and non-ST-segment elevation myocardial infartion.23008471Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AACirculationGuided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62.Circulation2012-09-25T00:00:002012Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.16490825Armstrong EJ, Morrow DA, Sabatine MSCirculationInflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation. 2006 Feb 21; 113(7):e152-5.Circulation2006-02-21T00:00:002006Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activation.Malhotra R, Sabatine MSHeart and Metabolism.Risk stratification and outcome in non-ST elevation acute coronary syndromes. Heart and Metabolism. 2004; 23:13-8.2004-01-01T00:00:002004Risk stratification and outcome in non-ST elevation acute coronary syndromes18237589Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CMThe American journal of cardiologyAssociation of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study). Am J Cardiol. 2008 Feb 01; 101(3):303-7.Am J Cardiol2007-12-20T00:00:002007Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study).18378613Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RTCirculationComplementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008 Apr 15; 117(15):1936-44.Circulation2008-03-31T00:00:002008Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.19596694Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, Sabatine MS, Gerszten RE, Carr SAMolecular & cellular proteomics : MCPQuantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics. 2009 Oct; 8(10):2339-49.Mol Cell Proteomics2009-07-13T00:00:002009Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.20886236Li Y, Sabatine MS, Tong CH, Ford I, Kirchgessner TG, Packard CJ, Robertson M, Rowland CM, Bare LA, Shepherd J, Devlin JJ, Iakoubova OAHuman geneticsGenetic variants in the KIF6 region and coronary event reduction from statin therapy. Hum Genet. 2011 Jan; 129(1):17-23.Hum Genet2010-10-01T00:00:002010Genetic variants in the KIF6 region and coronary event reduction from statin therapy.Authorship 1082255229986970Bonaca MP, Sabatine MSCirculationResponse by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)". Circulation. 2018 07 10; 138(2):222-223.Circulation2018-07-10T00:00:002018Response by Bonaca and Sabatine to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)".Authorship 11198815Gibson CM, Kirtane AJ, Aroesty JM, Murphy SA, Oman H, Takao S, Sabatine MS, Cannon CP, Braunwald E.CirculationClopidogrel Is Associated with Improved Angiographic Measures in ST Elevation Myocardial Infarction: A CLARITY-TIMI 28 Substudy. Circulation. 2005; 112(Suppl II):II-568.2005-11-06T00:00:002005Clopidogrel Is Associated with Improved Angiographic Measures in ST Elevation Myocardial Infarction: A CLARITY-TIMI 28 SubstudySabatine MS, O'Gara PT, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Acute myocardial infarction. Lilly LS, ed. Pathophysiology of Heart Disease. 1998; 145-69.1998-01-02T00:00:001998Acute myocardial infarctionAuthorship 1086047130073316Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RPJAMA cardiologyEfficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018 09 01; 3(9):823-828.JAMA Cardiol2018-09-01T00:00:002018Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.Authorship 102644318594042O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Wallentin L, Windhausen F, Sabatine MSJAMAEarly invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2008 Jul 02; 300(1):71-80.JAMA2008-07-02T00:00:002008Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.19106084Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MSThe New England journal of medicineCytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 Jan 22; 360(4):354-62.N Engl J Med2008-12-22T00:00:002008Cytochrome p-450 polymorphisms and response to clopidogrel.19679245O'Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SDJournal of the American College of CardiologyThe efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol. 2009 Aug 18; 54(8):678-85.J Am Coll Cardiol2009-08-18T00:00:002009The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.19940289Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald EThe New England journal of medicineA sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009 Dec 24; 361(26):2538-47.N Engl J Med2009-11-25T00:00:002009A sensitive cardiac troponin T assay in stable coronary artery disease.30145941Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BMThe New England journal of medicineCardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med. 2018 09 20; 379(12):1107-1117.N Engl J Med2018-08-26T00:00:002018Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.22096031Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, Murphy SA, Braunwald E, Lee RT, Morrow DAClinical chemistryRole of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012 Jan; 58(1):257-66.Clin Chem2011-11-17T00:00:002011Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial.Authorship 109046825Sabatine MSLilly LS, ed. Braunwald's Heart Disease: Review and Assessment.Part III. Lilly LS, ed. Braunwald's Heart Disease: Review and Assessment. 2001; 119-238.2001-01-01T00:00:002001Part IIISabatine MS, Cannon CP.Clopidogrel in ST-Elevation Myocardial Infarction.Clopidogrel in ST-Elevation Myocardial Infarction. 2005.2005-01-01T00:00:002005Clopidogrel in ST-Elevation Myocardial Infarction20505214Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten REScience translational medicineMetabolic signatures of exercise in human plasma. Sci Transl Med. 2010 May 26; 2(33):33ra37.Sci Transl Med2010-05-26T00:00:002010Metabolic signatures of exercise in human plasma.20843252Sabatine MS, Jaffer FA, Staats PN, Stone JRThe New England journal of medicineCase records of the Massachusetts General Hospital. Case 28-2010. A 32-year-old woman, 3 weeks post partum, with substernal chest pain. N Engl J Med. 2010 Sep 16; 363(12):1164-73.N Engl J Med2010-09-16T00:00:002010Case records of the Massachusetts General Hospital. Case 28-2010. A 32-year-old woman, 3 weeks post partum, with substernal chest pain.Authorship 10943171530239711Berg DD, Wiviott SD, Braunwald E, Guo J, Im K, Kashani A, Gibson CM, Cannon CP, Morrow DA, Bhatt DL, Mega JL, O'Donoghue ML, Antman EM, Newby LK, Sabatine MS, Giugliano RPEuropean heart journalModes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.Eur Heart J2018-11-07T00:00:002018Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.Sabatine, MS, ed.Medical TherapeuticsMedical Therapeutics. 2007.2007-01-01T00:00:002007Medical TherapeuticsGibson CM, Haim M, Aroesty JM, Ciaglo L, Shui A, Southard M, Harrigan C, Takao S, Marble SJ, Kirtane AJ, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson ME.Circulation.Association of ventricular fibrillation and ventricular tachycardia (VT/VF) with impaired TIMI Myocardial Perfusion Grades (TMPG) even in the presence of normal TIMI Grade 3 flow. Circulation. 2006; 114(Suppl II):II-706.2006-01-01T00:00:002006Association of ventricular fibrillation and ventricular tachycardia (VT/VF) with impaired TIMI Myocardial Perfusion Grades (TMPG) even in the presence of normal TIMI Grade 3 flowSabatine MS, Auchincloss HSolez K, Racusen LC, Billingham ME, eds. Solid Organ Transplant Rejection.Cell-mediated rejection. Solez K, Racusen LC, Billingham ME, eds. Solid Organ Transplant Rejection. 1996; 1-27.1996-01-01T00:00:001996Cell-mediated rejectionAuthorship 10970662530271950Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Nielsen JB, Jonsson S, Halldorsson GH, Melsted P, Ivarsdottir EV, Davidsson OB, Kristjansson RP, Thorleifsson G, Helgadottir A, Gretarsdottir S, Norddahl G, Rajamani S, Torfason B, Valgardsson AS, Sverrisson JT, Tragante V, Holmen OL, Asselbergs FW, Roden DM, Darbar D, Pedersen TR, Sabatine MS, Willer CJ, Løchen ML, Halldorsson BV, Jonsdottir I, Hveem K, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson KCommunications biologyCoding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun Biol. 2018; 1:68.Commun Biol2018-06-12T00:00:002018Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation.16143698Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald EJAMAEffect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224-32.JAMA2005-09-04T00:00:002005Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.18036447de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald EJournal of the American College of CardiologySerial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007 Nov 27; 50(22):2117-24.J Am Coll Cardiol2007-11-13T00:00:002007Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.Wiviott SD, Morrow DA, Sabatine MS, Giugliano GR, Guo W, Jarolim P, Gibson CM, Cannon CP, Braunwald E.Circulation.Baseline Cystatin C Measurement is a Potent Predictor of Adverse Cardiovascular Outcomes Following ACS: A PROVE IT - TIMI 22 Analysis. Circulation. 2006; 114(Suppl II):II-419.2006-01-01T00:00:002006Baseline Cystatin C Measurement is a Potent Predictor of Adverse Cardiovascular Outcomes Following ACS: A PROVE IT - TIMI 22 AnalysisScirica BM, Morrow DA, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, McCabe CH, Antman EM, Braunwald E.Circulation.Enoxaparin reduces recurrent MI and death in patients with STEMI undergoing fibrinolysis who achieve early ST resolution: The ExTRACT-TIMI 25 ECG Study. Circulation. 2006; 114(Suppl II):II-743.2006-01-01T00:00:002006Enoxaparin reduces recurrent MI and death in patients with STEMI undergoing fibrinolysis who achieve early ST resolution: The ExTRACT-TIMI 25 ECG StudyAuthorship 11044715Authorship 110770026Authorship 1100681230293771Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SDLancet (London, England)Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet. 2018 11 24; 392(10161):2269-2279.Lancet2018-10-04T00:00:002018Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.30326490O'Donnell CJ, Sabatine MSJAMA cardiologyOpportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design. JAMA Cardiol. 2018 10 01; 3(10):967.JAMA Cardiol2018-10-01T00:00:002018Opportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design.30301542Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MSThe American journal of cardiologyWITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management. Am J Cardiol. 2018 Aug 16.Am J Cardiol2018-08-16T00:00:002018WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.7577806Ljunggren HG, Van Kaer L, Sabatine MS, Auchincloss H, Tonegawa S, Ploegh HLInternational immunologyMHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice. Int Immunol. 1995 Jun; 7(6):975-84.Int Immunol1995-06-01T00:00:001995MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.Johannsen EC, Sabatine MSPharmCardsPharmCards. 2006.2006-12-26T00:00:002006PharmCardsAuthorship 121697310214473Sabatine MS, Jang IKActa cardiologicaAntithrombotic therapy in acute coronary syndromes. Acta Cardiol. 1999 Feb; 54(1):3-29.Acta Cardiol1999-02-01T00:00:001999Antithrombotic therapy in acute coronary syndromes.Sabatine MS, O'Gara PT, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Ischemic heart disease. Lilly LS, ed. Pathophysiology of Heart Disease. 1998; 119-43.1998-01-01T00:00:001998Ischemic heart diseaseWiviott SD, Morrow DA, O’Donoghue M, Sabatine MS, Murphy SA, Cannon CP.J Am Coll CardiolThe TIMI Risk Index for myocardial infarction predicts post-MI LV ejection fraction: a CLARITY-TIMI 28 substudy. J Am Coll Cardiol. 2006; 47(Suppl A):224A.2006-01-01T00:00:002006The TIMI Risk Index for myocardial infarction predicts post-MI LV ejection fraction: a CLARITY-TIMI 28 substudyAuthorship 111292020Authorship 111413315Authorship 1114148130415602Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MSThe New England journal of medicineDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 01 24; 380(4):347-357.N Engl J Med2018-11-10T00:00:002018Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.30420622Sabatine MSNature reviews. CardiologyPCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019 03; 16(3):155-165.Nat Rev Cardiol2019-03-01T00:00:002019PCSK9 inhibitors: clinical evidence and implementation.30424892Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MSLancet (London, England)SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 01 05; 393(10166):31-39.Lancet2018-11-10T00:00:002018SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.14757697Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald ECirculationImplications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.Circulation2004-02-02T00:00:002004Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.16344383Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RECirculationMetabolomic identification of novel biomarkers of myocardial ischemia. Circulation. 2005 Dec 20; 112(25):3868-75.Circulation2005-12-12T00:00:002005Metabolomic identification of novel biomarkers of myocardial ischemia.16549641Sabatine MS, Seidman JG, Seidman CECirculationCardiovascular genomics. Circulation. 2006 Mar 21; 113(11):e450-5.Circulation2006-03-21T00:00:002006Cardiovascular genomics.16618821Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JACirculationPrevalence and determinants of troponin T elevation in the general population. Circulation. 2006 Apr 25; 113(16):1958-65.Circulation2006-04-17T00:00:002006Prevalence and determinants of troponin T elevation in the general population.16847150Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald ECirculationClinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006 Jul 25; 114(4):281-8.Circulation2006-07-17T00:00:002006Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.17426196Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmor D, Kosmidou I, Jarolim P, de Lemos JA, Sabatine MS, Gibson CM, Morrow DChestDiagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest. 2007 Apr; 131(4):964-71.Chest2007-04-01T00:00:002007Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema.19249423Giraldez RR, Sabatine MS, Morrow DA, Mohanavelu S, McCabe CH, Antman EM, Braunwald EAmerican heart journalBaseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. Am Heart J. 2009 Mar; 157(3):517-24.Am Heart J2009-03-01T00:00:002009Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction.19958964Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CPJournal of the American College of CardiologyEffect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 08; 54(24):2290-5.J Am Coll Cardiol2009-12-08T00:00:002009Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.Authorship 112147424Authorship 11198337Authorship 11200261030571502Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Diaz R, Van de Werf F, Corbalán R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MSJournal of the American Heart AssociationReduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. J Am Heart Assoc. 2018 11 20; 7(22):e009260.J Am Heart Assoc2018-11-20T00:00:002018Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.30540337Qamar A, Giugliano RP, Keech AC, Kuder JF, Murphy SA, Kurtz CE, Wasserman SM, Sever PS, Pedersen TR, Sabatine MSJAMA cardiologyInterindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data. JAMA Cardiol. 2019 01 01; 4(1):59-63.JAMA Cardiol2019-01-01T00:00:002019Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.30561610Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZAEuropean heart journalPersistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. 2019 09 01; 40(33):2775-2781.Eur Heart J2019-09-01T00:00:002019Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.Authorship 112230818Authorship 11217012030586726Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SDCirculationLorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation. 2019 01 15; 139(3):366-375.Circulation2019-01-15T00:00:002019Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.30586750O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceška R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoglu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MSCirculationLipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 03 19; 139(12):1483-1492.Circulation2019-03-19T00:00:002019Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.11005941Sabatine MS, Tu TM, Jang IKJournal of thrombosis and thrombolysisCombination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. J Thromb Thrombolysis. 2000 Oct; 10(2):189-96.J Thromb Thrombolysis2000-10-01T00:00:002000Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.12644346Sabatine MS, Antman EMJournal of the American College of CardiologyThe thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003 Feb 19; 41(4 Suppl S):89S-95S.J Am Coll Cardiol2003-02-19T00:00:002003The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.16814646Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald EJournal of the American College of CardiologyThe role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.J Am Coll Cardiol2006-06-12T00:00:002006The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study.17008591Iakoubova OA, Tong CH, Chokkalingam AP, Rowland CM, Kirchgessner TG, Louie JZ, Ploughman LM, Sabatine MS, Campos H, Catanese JJ, Leong DU, Young BA, Lew D, Tsuchihashi Z, Luke MM, Packard CJ, Zerba KE, Shaw PM, Shepherd J, Devlin JJ, Sacks FMArteriosclerosis, thrombosis, and vascular biologyAsp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arterioscler Thromb Vasc Biol. 2006 Dec; 26(12):2763-8.Arterioscler Thromb Vasc Biol2006-09-28T00:00:002006Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.Authorship 110836218032767Sabatine MS, Poh KK, Mega JL, Shepard JA, Stone JR, Frosch MPThe New England journal of medicineCase records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension. N Engl J Med. 2007 Nov 22; 357(21):2167-78.N Engl J Med2007-11-22T00:00:002007Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension.19332592Sabatine MSCleveland Clinic journal of medicineNovel antiplatelet strategies in acute coronary syndromes. Cleve Clin J Med. 2009 Apr; 76 Suppl 1:S8-15.Cleve Clin J Med2009-04-01T00:00:002009Novel antiplatelet strategies in acute coronary syndromes.Authorship 11298071530694319Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano ALJAMAAssociation of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019 01 29; 321(4):364-373.JAMA2019-01-29T00:00:002019Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.Authorship 1076401Authorship 11367019Authorship 113766015Authorship 113961222Authorship 11390631830786725Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MSCirculationComparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019 04 23; 139(17):2022-2031.Circulation2019-04-23T00:00:002019Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.30882238Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SDCirculationEffect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536.Circulation2019-03-18T00:00:002019Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.30882239Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SDCirculationDapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019 05 28; 139(22):2516-2527.Circulation2019-03-18T00:00:002019Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.30773798Bergmark BA, Udell JA, Morrow DA, Jarolim P, Kuder JF, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MSEuropean journal of heart failureKlotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial. Eur J Heart Fail. 2019 04; 21(4):462-470.Eur J Heart Fail2019-02-18T00:00:002019Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.Authorship 13014926D008078Chemicals & Drugs64123340.491911Cholesterol, LDLD005960Chemicals & Drugs1154240.740067GlucosidesD000924Chemicals & Drugs2789790.567618Anticholesteremic AgentsD009203Disorders1626116680.217433Myocardial InfarctionAuthorship 11423351030895697McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SDEuropean journal of heart failureA trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 2019 05; 21(5):665-675.Eur J Heart Fail2019-03-21T00:00:002019A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).D001559Chemicals & Drugs2618190.625107Benzhydryl CompoundsAuthorship 1148895731020897Zelniker TA, Jarolim P, Scirica BM, Braunwald E, Park JG, Das S, Sabatine MS, Morrow DAJournal of the American Heart AssociationBiomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes. J Am Heart Assoc. 2019 05 07; 8(9):e011444.J Am Heart Assoc2019-05-07T00:00:002019Biomarker of Collagen Turnover (C-Terminal Telopeptide) and Prognosis in Patients With Non- ST -Elevation Acute Coronary Syndromes.Authorship 1149998331042267Qamar A, Giugliano RP, Sabatine MSJAMA cardiologyInterindividual and Intraindividual Responses to PCSK9 Inhibition-Reply. JAMA Cardiol. 2019 06 01; 4(6):600-601.JAMA Cardiol2019-06-01T00:00:002019Interindividual and Intraindividual Responses to PCSK9 Inhibition-Reply.Authorship 1151524331067395Wiviott SD, Raz I, Sabatine MSThe New England journal of medicineDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply. N Engl J Med. 2019 05 09; 380(19):1881-1882.N Engl J Med2019-05-09T00:00:002019Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.MedicineCardiologyBrigham and Women's HospitalSDW3StephenWiviottStephen Daniel Wiviott, M.D.42.33803410000000-71.0928603000000017932Wiviott, StephenProfessor of MedicineAuthorship 12005411MB91MarcBonacaMarc Peter Bonaca, M.D.42.33510370000000-71.1061649000000052829Bonaca, MarcLecturer on Medicine, Part-timeDLB20DeepakBhattDeepak L. Bhatt, M.D.42.33510370000000-71.1061649000000081016Bhatt, DeepakVisiting Professor of MedicineSDS3ScottSolomonScott David Solomon, M.D.42.33510370000000-71.1061649000000037443Solomon, ScottProfessor of MedicineYS25Yee-PingSunYee-Ping Sun, M.D.42.33510370000000-71.1061649000000052737Sun, Yee-PingAssistant Professor of MedicineMLO5MichelleO'DonoghueMichelle Louise O'Donoghue, M.D.42.33573100000000-71.1050570000000012709O'Donoghue, MichelleAssociate Professor of MedicineAuthorship 11561141731116355Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, Jukema JW, Toth K, Tikkanen MJ, Im K, Wiviott SD, Kurtz CE, Honarpour N, Giugliano RP, Keech AC, Sever PS, Sabatine MSJAMA cardiologyEffect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cardiol. 2019 07 01; 4(7):613-619.JAMA Cardiol2019-07-01T00:00:002019Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.PSS2PiotrSobieszczykPiotr Stefan Sobieszczyk, M.D.42.33510370000000-71.1061649000000083998Sobieszczyk, PiotrInstructor in MedicineASD3AkshayDesaiAkshay Suvas Desai, M.D.42.33510370000000-71.1061649000000073860Desai, AkshayAssociate Professor of Medicine11568selected publications12.37540.00491283781research areas16.51090.0127778161coauthor of1684.06105.81360similar toSK337SunilKapurSunil Kapur, M.D.42.33510370000000-71.1061649000000082399Kapur, SunilAssistant Professor of MedicineAuthorship 116128823Authorship 116104818Authorship 11625072Authorship 11612981Authorship 11614992031196453Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RPJournal of the American College of CardiologyEfficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol. 2019 06 18; 73(23):2961-2970.J Am Coll Cardiol2019-06-18T00:00:002019Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.31183961Sabatine MS, Giugliano RP, Leiter LADiabetes, obesity & metabolismCorrectly understanding the diabetes data in FOURIER. Diabetes Obes Metab. 2019 10; 21(10):2342-2343.Diabetes Obes Metab2019-07-04T00:00:002019Correctly understanding the diabetes data in FOURIER.31202949Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJJACC. Cardiovascular interventionsUpdated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.JACC Cardiovasc Interv2019-06-12T00:00:002019Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.31196815Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz IThe lancet. Diabetes & endocrinologyEffects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 08; 7(8):606-617.Lancet Diabetes Endocrinol2019-06-10T00:00:002019Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.31218354Dellborg M, Bonaca MP, Storey RF, Steg PG, Im KA, Cohen M, Bhatt DL, Oude Ophuis T, Budaj A, Hamm C, Spinar J, Kiss RG, Lopez-Sendon J, Kamensky G, Van de Werf F, Ardissino D, Kontny F, Montalescot G, Johanson P, Bengtsson O, Himmelmann A, Braunwald E, Sabatine MSEuropean heart journal. Cardiovascular pharmacotherapyEfficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019 10 01; 5(4):200-206.Eur Heart J Cardiovasc Pharmacother2019-10-01T00:00:002019Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.RPG1RobertGiuglianoRobert Patrick Giugliano, M.D.42.33864350000000-71.1068662000000065551Giugliano, RobertProfessor of MedicineCPC1ChristopherCannonChristopher Paul Cannon, M.D.42.33510370000000-71.1061649000000077834Cannon, ChristopherProfessor of MedicineEB3EugeneBraunwaldEugene Braunwald, M.D.42.33864350000000-71.1068662000000062123Braunwald, EugeneHersey Distinguished Professor of the Theory and Practice of PhysicSC136SusanChengSusan Cheng, M.D.42.33510370000000-71.1061649000000076068Cheng, SusanLecturer on Medicine, Part-timeAuthorship 11704701031309699McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SDEuropean journal of heart failureThe Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019 11; 21(11):1402-1411.Eur J Heart Fail2019-07-15T00:00:002019The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.Authorship 1389853Authorship 11742961Authorship 1175431931334749Sabatine MSEuropean heart journalPCSK9 inhibitors: what we know, what we should have understood, and what is to come. Eur Heart J. 2022 Feb 12; 43(7):e29-e31.Eur Heart J2022-02-12T00:00:002022PCSK9 inhibitors: what we know, what we should have understood, and what is to come.31331193Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, Collins RCirculationImpact of ADCY9 Genotype on Response to Anacetrapib. Circulation. 2019 Sep 10; 140(11):891-898.Circulation2019-07-23T00:00:002019Impact of ADCY9 Genotype on Response to Anacetrapib.Authorship 1181613431423992Zelniker TA, Wiviott SD, Raz I, Sabatine MSLancet (London, England)SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply. Lancet. 2019 08 17; 394(10198):560-561.Lancet2019-08-17T00:00:002019SGLT-2 inhibitors for people with type 2 diabetes - Authors' reply.Authorship 118720518Authorship 11867221631474116Berg DD, Wiviott SD, Scirica BM, Gurmu Y, Mosenzon O, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Johansson PA, Langkilde AM, Raz I, Braunwald E, Sabatine MSCirculationHeart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation. 2019 11 05; 140(19):1569-1577.Circulation2019-08-31T00:00:002019Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.31475726Ference BA, Bhatt DL, Catapano AL, Packard CJ, Graham I, Kaptoge S, Ference TB, Guo Q, Laufs U, Ruff CT, Cupido A, Hovingh GK, Danesh J, Holmes MV, Smith GD, Ray KK, Nicholls SJ, Sabatine MSJAMAAssociation of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019 Oct 08; 322(14):1381-1391.JAMA2019-10-08T00:00:002019Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease.Authorship 11904728Authorship 11916148Authorship 11894071831535829McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AMThe New England journal of medicineDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 11 21; 381(21):1995-2008.N Engl J Med2019-09-19T00:00:002019Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.31530008Marston NA, Giugliano RP, Im K, Silverman MG, O'Donoghue ML, Wiviott SD, Ference BA, Sabatine MSCirculationAssociation Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019 10 15; 140(16):1308-1317.Circulation2019-09-18T00:00:002019Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.31504418Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund OEuropean heart journal2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 01 01; 41(1):111-188.Eur Heart J2020-01-01T00:00:0020202019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Authorship 1204383Authorship 1199517231648705Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Ruzza A, Ma Y, Hamer AW, Wasserman SM, Raal FJJournal of the American College of CardiologyLong-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.J Am Coll Cardiol2019-10-29T00:00:002019Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.Authorship 12014352Authorship 12007134031657959Kato ET, Sabatine MS, Wiviott SDCirculationResponse by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus". Circulation. 2019 10 29; 140(18):e740-e741.Circulation2019-10-28T00:00:002019Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".31676222McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MSThe lancet. Diabetes & endocrinologyOdanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet Diabetes Endocrinol. 2019 12; 7(12):899-911.Lancet Diabetes Endocrinol2019-10-31T00:00:002019Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.Authorship 1407704Authorship 120596615Authorship 120394114Authorship 12044791231707849Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, Pedersen TR, Keech AC, Wang H, Lira Pineda A, Giugliano RP, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CTCirculationPredicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial. Circulation. 2020 02 25; 141(8):616-623.Circulation2019-11-11T00:00:002019Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.31736335Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, DeMets DL, Inzucchi SE, Køber L, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Lindholm D, Niklasson A, Sjöstrand M, Langkilde AM, McMurray JJVCirculationEffects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation. 2020 01 14; 141(2):90-99.Circulation2019-11-17T00:00:002019Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.31736328Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang CE, Tereshchenko S, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Ponikowski P, Sabatine MS, DeMets DL, Dutkiewicz-Piasecka M, Bengtsson O, Sjöstrand M, Langkilde AM, Jhund PS, McMurray JJVCirculationEfficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation. 2020 01 14; 141(2):100-111.Circulation2019-11-17T00:00:002019Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.true1Professor of MedicineProfessor of Medicinetrue1Instructor in MedicineInstructor in Medicinetrue1Assistant Professor of MedicineAssistant Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Lecturer on Medicine, Part-timeLecturer on Medicine, Part-timetrue1Associate Professor of MedicineAssociate Professor of Medicinetrue1Professor of MedicineProfessor of Medicinetrue1Lecturer on Medicine, Part-timeLecturer on Medicine, Part-timeAuthorship 1281691Authorship 12081061731811715Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MPEuropean heart journalLong-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020 05 01; 41(17):1625-1632.Eur Heart J2020-05-01T00:00:002020Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.Authorship 121233118Authorship 121099316Authorship 1212828631841369Butler J, Packer M, Greene SJ, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CMCirculationHeart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. Circulation. 2019 12 17; 140(25):2108-2118.Circulation2019-12-16T00:00:002019Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.31815543Skranes JB, Claggett BL, Myhre PL, Lyngbakken MN, Solomon SD, Sabatine MS, Pfeffer MA, Omland TCirculationCurrent Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial. Circulation. 2019 12 10; 140(24):2044-2046.Circulation2019-12-09T00:00:002019Current Smoking Is Associated With Lower Concentrations of High-Sensitivity Cardiac Troponin T in Patients With Stable Coronary Artery Disease: The PEACE Trial.31843945Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz IDiabetes careEfficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. Diabetes Care. 2020 02; 43(2):468-475.Diabetes Care2019-12-16T00:00:002019Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.Authorship 12141361231865968Sarma AA, Braunwald E, Cannon CP, Guo J, Im K, Antman EM, Gibson CM, Newby LK, Giugliano RP, Morrow DA, Wiviott SD, Sabatine MS, O'Donoghue MLJournal of the American College of CardiologyOutcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.J Am Coll Cardiol2019-12-09T00:00:002019Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes.Authorship 122042115Authorship 1219668631969016Barnett JV, Beckman JA, Bonaca MP, Carnethon MR, Cassis LA, Creager MA, Daugherty A, Feinberg MW, Freiberg MS, Goodney PP, Greenland P, Leeuwenburgh C, LeMaire SA, McDermott MM, Sabatine MS, Shen YH, Wasserman DH, Webb NR, Wells QSArteriosclerosis, thrombosis, and vascular biologyAmerican Heart Association Vascular Disease Strategically Focused Research Network. Arterioscler Thromb Vasc Biol. 2020 03; 40(3):e47-e54.Arterioscler Thromb Vasc Biol2020-01-23T00:00:002020American Heart Association Vascular Disease Strategically Focused Research Network.31976867Furtado RHM, Nicolau JC, Guo J, Im K, White JA, Sabatine MS, Newby LK, Giugliano RPJournal of the American College of CardiologyMorphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. J Am Coll Cardiol. 2020 01 28; 75(3):289-300.J Am Coll Cardiol2020-01-28T00:00:002020Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography.Authorship 1174081Authorship 12221521731983236Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SDCirculationEffect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 04 14; 141(15):1227-1234.Circulation2020-01-27T00:00:002020Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.Authorship 1223037932019364Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O'Donoghue MLEuropean journal of preventive cardiologyLDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol. 2020 Feb 04; 2047487320902750.Eur J Prev Cardiol2020-02-04T00:00:002020LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.Authorship 12296721232090404Bajaj HS, Raz I, Mosenzon O, Murphy SA, Rozenberg A, Yanuv I, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Sabatine MS, Wiviott SD, Cahn ADiabetes, obesity & metabolismCardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020 07; 22(7):1122-1131.Diabetes Obes Metab2020-03-12T00:00:002020Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial.Authorship 1234503732164882Scirica BM, Bergmark BA, Morrow DA, Antman EM, Bonaca MP, Murphy SA, Sabatine MS, Braunwald E, Wiviott SDJournal of the American College of CardiologyNonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2020 03 17; 75(10):1095-1106.J Am Coll Cardiol2020-03-17T00:00:002020Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.Authorship 12360183132219386Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJVJAMAEffect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020 04 14; 323(14):1353-1368.JAMA2020-04-14T00:00:002020Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.Authorship 123686815Authorship 12370259Authorship 12374001732221582Docherty KF, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Desai AS, Diez M, Howlett JG, Katova T, Ljungman CEA, O'Meara E, Petrie MC, Schou M, Verma S, Vinh PN, Solomon SD, McMurray JJVEuropean heart journalEffects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020 07 01; 41(25):2379-2392.Eur Heart J2020-07-01T00:00:002020Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.32223429Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MSCirculationThe Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism. Circulation. 2020 05 19; 141(20):1600-1607.Circulation2020-03-29T00:00:002020The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.32239659Cahn A, Raz I, Bonaca M, Mosenzon O, Murphy SA, Yanuv I, Rozenberg A, Wilding JPH, Bhatt DL, McGuire DK, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Jermendy G, Hadjadj S, Langkilde AM, Sabatine MS, Wiviott SD, Leiter LADiabetes, obesity & metabolismSafety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. Diabetes Obes Metab. 2020 08; 22(8):1357-1368.Diabetes Obes Metab2020-04-27T00:00:002020Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study.32327085Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin LJACC. Cardiovascular interventionsNo Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC Cardiovasc Interv. 2020 04 27; 13(8):1012-1014.JACC Cardiovasc Interv2020-04-27T00:00:002020No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.32312223Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, Murphy SA, Wasserman SM, Honarpour N, Wang H, Lira Pineda A, Sabatine MSStrokeStroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 05; 51(5):1546-1554.Stroke2020-04-21T00:00:002020Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.Authorship 124197212Authorship 12422871Authorship 124329018Authorship 12433831532347887Bergmark BA, O'Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceška R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MSJAMA cardiologyAn Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiol. 2020 06 01; 5(6):709-713.JAMA Cardiol2020-06-01T00:00:002020An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.32347885Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MSJAMA cardiologyEffect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2020 07 01; 5(7):787-793.JAMA Cardiol2020-07-01T00:00:002020Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial.Authorship 1769752Authorship 124556711Authorship 12457291332366163Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, Bhatt DL, Steg PG, Storey RF, Johanson P, Wang Z, Hazen SL, Sabatine MSJournal of the American Heart AssociationGut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2020 05 18; 9(10):e015331.J Am Heart Assoc2020-05-05T00:00:002020Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.32381158Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pedersen TR, Keech AC, Ott BR, Sabatine MS, Giugliano RPJournal of the American College of CardiologyCognition After Lowering LDL-Cholesterol With Evolocumab. J Am Coll Cardiol. 2020 05 12; 75(18):2283-2293.J Am Coll Cardiol2020-05-12T00:00:002020Cognition After Lowering LDL-Cholesterol With Evolocumab.Authorship 12482341432432684Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RPJAMA cardiologyEfficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. JAMA Cardiol. 2020 08 01; 5(8):952-957.JAMA Cardiol2020-08-01T00:00:002020Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.Authorship 125420510Authorship 1255176332551860O'Donoghue ML, Murphy SA, Sabatine MSCirculationThe Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation. 2020 08 11; 142(6):538-545.Circulation2020-06-19T00:00:002020The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.32539224Dewan P, Solomon SD, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, DeMets DL, Sabatine MS, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Belohlávek J, Chopra VK, Dukát A, Kitakaze M, Merkely B, O'Meara E, Schou M, Vinh PN, McMurray JJVEuropean journal of heart failureEfficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail. 2020 07; 22(7):1247-1258.Eur J Heart Fail2020-06-15T00:00:002020Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.Authorship 1971931Authorship 1326655Authorship 13829010Authorship 126765612Authorship 126749324Authorship 1270021932653447Solomon SD, Jhund PS, Claggett BL, Dewan P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Inzucchi SE, Desai AS, Bengtsson O, Lindholm D, Sjostrand M, Langkilde AM, McMurray JJVJACC. Heart failureEffect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail. 2020 10; 8(10):811-818.JACC Heart Fail2020-07-08T00:00:002020Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.32683645Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL, Cange AL, Sabatine MS, O'Donoghue MLJournal of thrombosis and thrombolysisBiomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.J Thromb Thrombolysis2021-04-01T00:00:002021Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.32673497Jackson AM, Dewan P, Anand IS, Belohlávek J, Bengtsson O, de Boer RA, Böhm M, Boulton DW, Chopra VK, DeMets DL, Docherty KF, Dukát A, Greasley PJ, Howlett JG, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Ljungman CEA, Martinez FA, O'Meara E, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, Jhund PS, McMurray JJVCirculationDapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020 09 15; 142(11):1040-1054.Circulation2020-07-16T00:00:002020Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.Authorship 1611153Authorship 12750261232756916Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DAJAMA cardiologyClinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiol. 2020 11 01; 5(11):1255-1262.JAMA Cardiol2020-11-01T00:00:002020Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.Authorship 12777278Authorship 127866318Authorship 12780691032785614Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RPJAMA cardiologyEfficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021 02 01; 6(2):139-147.JAMA Cardiol2021-02-01T00:00:002021Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.32795086Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, McGuire DK, Goodrich EL, De Mendonca Furtado RH, Wilding JPH, Cahn A, Gause-Nilsson IAM, Johanson P, Fredriksson M, Johansson PA, Langkilde AM, Raz I, Sabatine MSCirculationDapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020 08 25; 142(8):734-747.Circulation2020-08-03T00:00:002020Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.32820334Serenelli M, Böhm M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Sjöstrand M, Langkilde AM, Anand IS, Chiang CE, Chopra VK, de Boer RA, Diez M, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Verma S, Docherty KF, Jhund PS, McMurray JJVEuropean heart journalEffect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J. 2020 09 21; 41(36):3402-3418.Eur Heart J2020-09-21T00:00:002020Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).Authorship 12802271732844557Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz IDiabetes, obesity & metabolismCardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021 01; 23(1):29-38.Diabetes Obes Metab2020-09-22T00:00:002020Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.Authorship 12827982332883108Docherty KF, Jhund PS, Anand I, Bengtsson O, Böhm M, de Boer RA, DeMets DL, Desai AS, Drozdz J, Howlett J, Inzucchi SE, Johanson P, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Nicolau JC, O'Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Tereshchenko S, Verma S, McMurray JJVCirculationEffect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Circulation. 2020 10 27; 142(17):1623-1632.Circulation2020-09-04T00:00:002020Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.Authorship 1288283332897752Zelniker TA, Raz I, Sabatine MS, Wiviott SDCirculationResponse by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". Circulation. 2020 09 08; 142(10):e129-e130.Circulation2020-09-08T00:00:002020Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial".Authorship 129551023Authorship 12963218Authorship 129785310Authorship 12982001933095249Xu H, Yang Y, Wang C, Yang J, Li W, Zhang X, Ye Y, Dong Q, Fu R, Sun H, Yan X, Gao X, Wang Y, Jia X, Sun Y, Wu Y, Zhang J, Zhao W, Sabatine MS, Wiviott SDJAMA network openAssociation of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China. JAMA Netw Open. 2020 10 01; 3(10):e2021677.JAMA Netw Open2020-10-01T00:00:002020Association of Hospital-Level Differences in Care With Outcomes Among Patients With Acute ST-Segment Elevation Myocardial Infarction in China.33040613Jhund PS, Solomon SD, Docherty KF, Heerspink HJL, Anand IS, Böhm M, Chopra V, de Boer RA, Desai AS, Ge J, Kitakaze M, Merkley B, O'Meara E, Shou M, Tereshchenko S, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, McMurray JJVCirculationEfficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Circulation. 2021 01 26; 143(4):298-309.Circulation2020-10-12T00:00:002020Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.33082245Docherty KF, Jhund PS, Bengtsson O, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJVDiabetes careEffect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care. 2020 11; 43(11):2878-2881.Diabetes Care2020-09-02T00:00:002020Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.33081496Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PGEuropean heart journal. Acute cardiovascular careOutcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Eur Heart J Acute Cardiovasc Care. 2020 10 20.Eur Heart J Acute Cardiovasc Care2020-10-20T00:00:002020Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy.Authorship 1300052333104403Marston NA, Ruff CT, Sabatine MSCirculationResponse by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism". Circulation. 2020 10 27; 142(17):e264.Circulation2020-10-26T00:00:002020Response by Marston et al to Letter Regarding Article, "The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism".33185476Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O'Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CTCirculationClinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.Circulation2020-11-13T00:00:002020Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.Authorship 2355041Authorship 13024596Authorship 130306112Authorship 130547427Authorship 13048892Authorship 13063322Authorship 13076989Authorship 1306762933175081Bergmark BA, Sabatine MSJAMA cardiologyPCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply. JAMA Cardiol. 2021 04 01; 6(4):481.JAMA Cardiol2021-04-01T00:00:002021PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply.33185670Marcusa DP, Giugliano RP, Park JG, de Lemos JA, Cannon CP, Sabatine MSJAMA cardiologyAssociation of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2020 Nov 13.JAMA Cardiol2020-11-13T00:00:002020Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition.33164553Yeoh SE, Dewan P, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Sjöstrand M, Langkilde AM, McMurray JJVCirculation. Heart failurePatient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy? Circ Heart Fail. 2020 12; 13(12):e007879.Circ Heart Fail2020-11-09T00:00:002020Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?33186535Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MSLancet (London, England)Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.Lancet2020-11-10T00:00:002020Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.33197560Oyama K, Furtado RHM, Fagundes A, Zelniker TA, Tang M, Kuder J, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BAJournal of the American College of CardiologyEffect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021 01 26; 77(3):259-267.J Am Coll Cardiol2020-11-13T00:00:002020Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization.33217334Aroda VR, Sabatine MSThe lancet. Diabetes & endocrinologyEMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction. Lancet Diabetes Endocrinol. 2020 12; 8(12):932-933.Lancet Diabetes Endocrinol2020-12-01T00:00:002020EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.Authorship 13088911733269486Zelniker TA, Morrow DA, Mosenzon O, Goodrich EL, Jarolim P, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Bode C, Lewis BS, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Wiviott SDEuropean journal of heart failureRelationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. Eur J Heart Fail. 2021 06; 23(6):1026-1036.Eur J Heart Fail2020-12-29T00:00:002020Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.Authorship 154932333284957O'Donoghue ML, Sabatine MSEuropean heart journalAspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting. Eur Heart J. 2021 01 21; 42(4):320-322.Eur Heart J2021-01-21T00:00:002021Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting.Authorship 13122062Authorship 131434718Authorship 1314993733368858Dewan P, Docherty KF, Bengtsson O, de Boer RA, Desai AS, Drozdz J, Hawkins NM, Inzucchi SE, Kitakaze M, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez FA, Merkely B, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Verma S, Jhund PS, McMurray JJVEuropean journal of heart failureEffects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. Eur J Heart Fail. 2021 04; 23(4):632-643.Eur J Heart Fail2021-01-18T00:00:002021Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.33355302Inzucchi SE, Docherty KF, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Verma S, Belohlávek J, Böhm M, Chiang CE, de Boer RA, Diez M, Dukát A, Ljungman CEA, Bengtsson O, Langkilde AM, Sjöstrand M, Jhund PS, McMurray JJVDiabetes careDapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 02; 44(2):586-594.Diabetes Care2020-12-18T00:00:002020Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF.Authorship 2052845Authorship 13212381Authorship 132182112Authorship 13228262133430604Dillinger JG, Ducrocq G, Elbez Y, Cohen M, Bode C, Pollack C, Petrauskiene B, Henry P, Dorobantu M, French WJ, Wiviott SD, Sabatine MS, Mehta SR, Steg PGCirculation. Cardiovascular interventionsSex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial. Circ Cardiovasc Interv. 2021 01; 14(1):e009759.Circ Cardiovasc Interv2021-01-12T00:00:002021Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial.33434447Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CTCirculation. Genomic and precision medicineGenetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circ Genom Precis Med. 2021 02; 14(1):e003006.Circ Genom Precis Med2021-01-12T00:00:002021Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease.33428482Sabatine MS, Giugliano RP, Schwartz GGExpert review of clinical pharmacologyLetter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'. Expert Rev Clin Pharmacol. 2021 02; 14(2):281-282.Expert Rev Clin Pharmacol2021-01-12T00:00:002021Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.Authorship 13235451333493256Bonaca MP, George RT, Morrow DA, Bergmark BA, Park JG, Abuhatzira L, Vavere AL, Karathanasis SK, Jin C, She D, Hirshberg B, Hsia J, Sabatine MSEuropean heart journal. Cardiovascular pharmacotherapyRecombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design. Eur Heart J Cardiovasc Pharmacother. 2022 05 05; 8(3):243-252.Eur Heart J Cardiovasc Pharmacother2022-05-05T00:00:002022Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design.Authorship 1325557733518473Abtan J, Wiviott SD, Sorbets E, Popovic B, Elbez Y, Mehta SR, Sabatine MS, Bode C, Pollack CV, Cohen M, Moccetti T, Laanmets P, Faxon D, Okreglicki A, Ducrocq G, Steg PGArchives of cardiovascular diseasesPrevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial. Arch Cardiovasc Dis. 2021 Mar; 114(3):187-196.Arch Cardiovasc Dis2021-01-29T00:00:002021Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.Authorship 132853617Authorship 13290391833559485Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MPJournal of the American Heart AssociationPredictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. J Am Heart Assoc. 2021 02 16; 10(4):e017008.J Am Heart Assoc2021-02-09T00:00:002021Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.33549554Shen L, Kristensen SL, Bengtsson O, Böhm M, de Boer RA, Docherty KF, Inzucchi SE, Katova T, Køber L, Kosiborod MN, Langkilde AM, Lindholm D, Martinez MFA, O'Meara E, Nicolau JC, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJVJACC. Heart failureDapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail. 2021 04; 9(4):254-264.JACC Heart Fail2021-02-03T00:00:002021Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.Authorship 133165112Authorship 13318068Authorship 133147216Authorship 13315961533587654Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, Bonaca MP, Cannon CP, Im K, Guo J, Sabatine MS, O'Donoghue MLCirculationSex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.Circulation2021-02-15T00:00:002021Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.33595593Berg DD, Jhund PS, Docherty KF, Murphy SA, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sjöstrand M, Solomon SD, McMurray JJV, Sabatine MSJAMA cardiologyTime to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021 05 01; 6(5):499-507.JAMA Cardiol2021-05-01T00:00:002021Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.33594755Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Bengtsson O, Jhund PS, McMurray JJV, Køber LEuropean journal of heart failureEfficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. Eur J Heart Fail. 2021 04; 23(4):601-613.Eur J Heart Fail2021-03-10T00:00:002021Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.33609103Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PGEuropean heart journal. Acute cardiovascular careOutcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. Eur Heart J Acute Cardiovasc Care. 2020 Oct 20.Eur Heart J Acute Cardiovasc Care2020-10-20T00:00:002020Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy.Authorship 133375611Authorship 13336587Authorship 13337461733615642Docherty KF, Curtain JP, Anand IS, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Schou M, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJVEuropean journal of heart failureEffect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail. 2021 04; 23(4):617-628.Eur J Heart Fail2021-03-22T00:00:002021Effect of dapagliflozin on anaemia in DAPA-HF.33611623O'Donoghue ML, Kato ET, Mosenzon O, Murphy SA, Cahn A, Herrera M, Tankova T, Šmahelová A, Merlini P, Gause-Nilsson I, Langkilde AM, McGuire DK, Wilding JPH, Leiter LA, Bhatt DL, Raz I, Sabatine MS, Wiviott SDDiabetologiaThe efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. Diabetologia. 2021 06; 64(6):1226-1234.Diabetologia2021-02-20T00:00:002021The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.33624052Gencer B, Morrow DA, Braunwald E, Goodrich EL, Hilvo M, Kauhanen D, Sabatine MS, Laaksonen R, O'Donoghue MLEuropean journal of preventive cardiologyPlasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. Eur J Prev Cardiol. 2022 05 06; 29(6):895-902.Eur J Prev Cardiol2022-05-06T00:00:002022Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.Authorship 13354421433653824Cahn A, Raz I, Leiter LA, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Wiviott SDDiabetes careCardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care. 2021 05; 44(5):1159-1167.Diabetes Care2021-03-02T00:00:002021Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.Authorship 134356619Authorship 13440301733787831Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O'Meara E, Katova T, Ljungman CEA, Diez M, Ogunniyi MO, Langkilde AM, Sjöstrand M, Lindholm D, Bengtsson O, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Jhund PS, McMurray JJV, Køber LJAMA cardiologyEfficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiol. 2021 06 01; 6(6):678-689.JAMA Cardiol2021-06-01T00:00:002021Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.33832352Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, Böhm M, Chiang CE, Desai AS, Howlett J, Kitakaze M, Petrie MC, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Sabatine MS, Solomon SD, McMurray JJVCirculationDapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation. 2021 05 18; 143(20):1962-1972.Circulation2021-04-09T00:00:002021Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF.Authorship 134842715Authorship 13469927Authorship 13494687Authorship 1350100133884889Berg DD, Freedman BL, Bonaca MP, Jarolim P, Scirica BM, Goodrich EL, Sabatine MS, Morrow DAJournal of the American Heart AssociationCardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.J Am Heart Assoc2021-04-22T00:00:002021Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50.33881457Sabatine MSJAMA cardiologyDifferentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science. JAMA Cardiol. 2021 07 01; 6(7):781.JAMA Cardiol2021-07-01T00:00:002021Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science.33840228Zelniker TA, Morrow DA, Scirica BM, Furtado JD, Guo J, Mozaffarian D, Sabatine MS, O'Donoghue MLJournal of the American Heart AssociationPlasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36. J Am Heart Assoc. 2021 04 20; 10(8):e017401.J Am Heart Assoc2021-04-12T00:00:002021Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.33851953Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SDJAMA cardiologyEffect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2021 07 01; 6(7):801-810.JAMA Cardiol2021-07-01T00:00:002021Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.33980763Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, Lu C, Tay L, Deedwania PC, Siu CW, Lira Pineda A, Choi D, Charng MJ, Amerena J, Wan Ahmad WA, Chopra VK, Pedersen TR, Giugliano RP, Sabatine MSCirculation journal : official journal of the Japanese Circulation SocietyEfficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circ J. 2021 10 25; 85(11):2063-2070.Circ J2021-05-15T00:00:002021Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.Authorship 135623919Authorship 1361026134082913Sabatine MS, Braunwald EJournal of the American College of CardiologyThrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. J Am Coll Cardiol. 2021 06 08; 77(22):2822-2845.J Am Coll Cardiol2021-06-08T00:00:002021Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8.Authorship 1823325Authorship 137129120Authorship 1371491334160553Wiviott SD, Giugliano RP, Sabatine MSJAMA cardiologyMyocardial Infarction and Evolocumab-Reply. JAMA Cardiol. 2021 10 01; 6(10):1222-1223.JAMA Cardiol2021-10-01T00:00:002021Myocardial Infarction and Evolocumab-Reply.34233928Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz IDiabetes careThe Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 08; 44(8):1805-1815.Diabetes Care2021-07-07T00:00:002021The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.34279993Marston NA, Oyama K, Jarolim P, Tang M, Sever PS, Keech AC, Lira Pineda A, Wang H, Giugliano RP, Sabatine MS, Morrow DACirculationCombining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 07 20; 144(3):249-251.Circulation2021-07-19T00:00:002021Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy.Authorship 13760321834272791Adamson C, Jhund PS, Docherty KF, Belohlávek J, Chiang CE, Diez M, Drozdz J, Dukát A, Howlett J, Ljungman CEA, Petrie MC, Schou M, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, Bengtsson O, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJVEuropean journal of heart failureEfficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021 10; 23(10):1662-1672.Eur J Heart Fail2021-07-29T00:00:002021Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.Authorship 137755710Authorship 1378032934298555Sever P, Gouni-Berthold I, Keech A, Giugliano R, Pedersen TR, Im K, Wang H, Knusel B, Sabatine MS, O'Donoghue MLEuropean journal of preventive cardiologyLDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol. 2021 07 23; 28(8):805-812.Eur J Prev Cardiol2020-02-04T00:00:002020LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial.Authorship 13801491234319398Docherty KF, Jhund PS, Claggett B, Ferreira JP, Bengtsson O, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, McMurray JJVJAMA cardiologyExtrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. JAMA Cardiol. 2021 11 01; 6(11):1298-1305.JAMA Cardiol2021-11-01T00:00:002021Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.Authorship 13884913Authorship 138912018Authorship 13888867Authorship 138865316Authorship 13888741034423649Bergmark BA, Bhatt DL, Steg PG, Budaj A, Storey RF, Gurmu Y, Kuder JF, Im K, Magnani G, Oude Ophuis T, Hamm C, Špinar J, Kiss RG, Van de Werf FJ, Montalescot G, Johanson P, Braunwald E, Sabatine MS, Bonaca MPJournal of the American Heart AssociationLong-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial. J Am Heart Assoc. 2021 09 07; 10(17):e020446.J Am Heart Assoc2021-08-21T00:00:002021Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.34427295Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Park KS, Goudev A, Diaz R, Špinar J, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SDEuropean heart journalObesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J. 2022 08 14; 43(31):2958-2967.Eur Heart J2022-08-14T00:00:002022Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.34448003Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJVEuropean heart journalEffect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021 09 21; 42(36):3727-3738.Eur Heart J2021-09-21T00:00:002021Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.34431967Marcusa DP, Giugliano RP, Sabatine MSJAMA cardiologyAssessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply. JAMA Cardiol. 2021 11 01; 6(11):1342-1343.JAMA Cardiol2021-11-01T00:00:002021Assessment of the Change of a Continuous Variable as a Function of its Initial Value-Reply.34452583Marston NA, Giugliano RP, Park JG, Ruzza A, Sever PS, Keech AC, Sabatine MSCirculationCardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL. Circulation. 2021 11 23; 144(21):1732-1734.Circulation2021-08-27T00:00:002021Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL.Authorship 139031211734480422Lumbers RT, Shah S, Lin H, Czuba T, Henry A, Swerdlow DI, Mälarstig A, Andersson C, Verweij N, Holmes MV, Ärnlöv J, Svensson P, Hemingway H, Sallah N, Almgren P, Aragam KG, Asselin G, Backman JD, Biggs ML, Bloom HL, Boersma E, Brandimarto J, Brown MR, Brunner-La Rocca HP, Carey DJ, Chaffin MD, Chasman DI, Chazara O, Chen X, Chen X, Chung JH, Chutkow W, Cleland JGF, Cook JP, de Denus S, Dehghan A, Delgado GE, Denaxas S, Doney AS, Dörr M, Dudley SC, Engström G, Esko T, Fatemifar G, Felix SB, Finan C, Ford I, Fougerousse F, Fouodjio R, Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S, Guðbjartsson DF, Gui H, Gutmann R, Haggerty CM, van der Harst P, Hedman ÅK, Helgadottir A, Hillege H, Hyde CL, Jacob J, Jukema JW, Kamanu F, Kardys I, Kavousi M, Khaw KT, Kleber ME, Køber L, Koekemoer A, Kraus B, Kuchenbaecker K, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan J, Magnusson P, Mahajan A, Mann D, Margulies KB, Marston NA, März W, McMurray JJV, Melander O, Melloni G, Mordi IR, Morley MP, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP, Newton-Cheh C, Niessner A, Niiranen T, Nowak C, O'Donoghue ML, Owens AT, Palmer CNA, Paré G, Perola M, Perreault LL, Portilla-Fernandez E, Psaty BM, Rice KM, Ridker PM, Romaine SPR, Roselli C, Rotter JI, Ruff CT, Sabatine MS, Salo P, Salomaa V, van Setten J, Shalaby AA, Smelser DT, Smith NL, Stefansson K, Stender S, Stott DJ, Sveinbjörnsson G, Tammesoo ML, Tardif JC, Taylor KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-Pedersen C, Trompet S, Tuckwell D, Tyl B, Uitterlinden AG, Vaura F, Veluchamy A, Visscher PM, Völker U, Voors AA, Wang X, Wareham NJ, Weeke PE, Weiss R, White HD, Wiggins KL, Xing H, Yang J, Yang Y, Yerges-Armstrong LM, Yu B, Zannad F, Zhao F, Wilk JB, Holm H, Sattar N, Lubitz SA, Lanfear DE, Shah S, Dunn ME, Wells QS, Asselbergs FW, Hingorani AD, Dubé MP, Samani NJ, Lang CC, Cappola TP, Ellinor PT, Vasan RS, Smith JGESC heart failureThe genomics of heart failure: design and rationale of the HERMES consortium. ESC Heart Fail. 2021 12; 8(6):5531-5541.ESC Heart Fail2021-09-03T00:00:002021The genomics of heart failure: design and rationale of the HERMES consortium.Authorship 139305910Authorship 13944901734508693Cavender MA, O'Donoghue ML, Abbate A, Aylward P, Fox KA, Glaser RX, Park JG, Lopez-Sendon J, Steg PG, Sabatine MS, Morrow DAAmerican heart journalInhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial. Am Heart J. 2022 01; 243:147-157.Am Heart J2021-09-08T00:00:002021Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial.34535469Berg DD, Wiviott SD, Scirica BM, Zelniker TA, Goodrich EL, Jarolim P, Mosenzon O, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Johanson P, Langkilde AM, Raz I, Braunwald E, Sabatine MS, Morrow DADiabetes careA Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 11; 44(11):2573-2581.Diabetes Care2021-09-17T00:00:002021A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.Authorship 13962461034537830Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, Ruzza A, Keech AC, Sever PS, Sabatine MS, Bergmark BAEuropean heart journalEffect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J. 2021 12 14; 42(47):4821-4829.Eur Heart J2021-12-14T00:00:002021Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.Authorship 1399351634620406Oyama K, Giugliano RP, Blazing MA, Park JG, Tershakovec AM, Sabatine MS, Cannon CP, Braunwald EJournal of the American College of CardiologyBaseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1499-1507.J Am Coll Cardiol2021-10-12T00:00:002021Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.Authorship 18427612Authorship 14066051734706556Ruff CT, Koren MJ, Grimsby J, Rosenbaum AI, Tu X, Karathanasis SK, Falloon J, Hsia J, Guan Y, Conway J, Tsai LF, Hummer BT, Hirshberg B, Kuder JF, Murphy SA, George RT, Sabatine MSArteriosclerosis, thrombosis, and vascular biologyLEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2021 12; 41(12):3005-3014.Arterioscler Thromb Vasc Biol2021-10-28T00:00:002021LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.Authorship 202928Authorship 140987219Authorship 14121221Authorship 141429511Authorship 141165314Authorship 141287515Authorship 14133441934743554Berg DD, Docherty KF, Sattar N, Jarolim P, Welsh P, Jhund PS, Anand IS, Chopra V, de Boer RA, Kosiborod MN, Nicolau JC, O'Meara E, Schou M, Hammarstedt A, Langkilde AM, Lindholm D, Sjöstrand M, McMurray JJV, Sabatine MS, Morrow DACirculationSerial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2022 01 18; 145(3):158-169.Circulation2021-11-08T00:00:002021Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.34766424Butt JH, Docherty KF, Jhund PS, de Boer RA, Böhm M, Desai AS, Howlett JG, Inzucchi SE, Kosiborod MN, Martinez FA, Nicolau JC, Petrie MC, Ponikowski P, Bengtsson O, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, McMurray JJV, Køber LEuropean journal of heart failureDapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. Eur J Heart Fail. 2022 03; 24(3):513-525.Eur J Heart Fail2021-11-24T00:00:002021Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF.34802253Butt JH, Adamson C, Docherty KF, de Boer RA, Petrie MC, Inzucchi SE, Kosiborod MN, Maria Langkilde A, Lindholm D, Martinez FA, Bengtsson O, Schou M, O'Meara E, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Jhund PS, McMurray JJV, Køber LCirculation. Heart failureEfficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circ Heart Fail. 2021 12; 14(12):e008837.Circ Heart Fail2021-11-22T00:00:002021Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.34793745Sabatine MS, Bergmark BA, Murphy SA, O'Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald ELancet (London, England)Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021 12 18; 398(10318):2247-2257.Lancet2021-11-15T00:00:002021Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.34856173Rossing P, Inzucchi SE, Vart P, Jongs N, Docherty KF, Jhund PS, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Solomon SD, DeMets DL, Bengtsson O, Lindberg M, Langkilde AM, Sjöstrand M, Stefansson BV, Karlsson C, Chertow GM, Hou FF, Correa-Rotter R, Toto RD, Wheeler DC, McMurray JJV, Heerspink HJLThe lancet. Diabetes & endocrinologyDapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022 01; 10(1):24-34.Lancet Diabetes Endocrinol2021-11-29T00:00:002021Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.34773460Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, Ference B, Stein E, Stroes ES, Braunwald E, Ellinor PT, Lubitz SA, Ruff CT, Sabatine MSJAMA cardiologyAssociation of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022 Mar 01; 7(3):250-256.JAMA Cardiol2022-03-01T00:00:002022Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.Authorship 1418259634873344Ruff CT, Baron M, Im K, O'Donoghue ML, Fiedorek FT, Sabatine MSNature medicineSubcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022 01; 28(1):89-95.Nat Med2021-12-06T00:00:002021Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.Authorship 2303245Authorship 14224151734969498Docherty KF, Ogunniyi MO, Anand IS, Desai AS, Diez M, Howlett JG, Nicolau JC, O'Meara E, Verma S, Inzucchi SE, Køber L, Kosiborod MN, Lindholm D, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJVJACC. Heart failureEfficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. JACC Heart Fail. 2022 01; 10(1):52-64.JACC Heart Fail2021-11-10T00:00:002021Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.35064721McDowell K, Welsh P, Docherty KF, Morrow DA, Jhund PS, de Boer RA, O'Meara E, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Hammarstedt A, Langkilde AM, Sjöstrand M, Lindholm D, Solomon SD, Sattar N, Sabatine MS, McMurray JJVEuropean journal of heart failureDapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. Eur J Heart Fail. 2022 06; 24(6):1066-1076.Eur J Heart Fail2022-02-06T00:00:002022Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.35034351Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner ARClinical pharmacology and therapeuticsClinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022 11; 112(5):959-967.Clin Pharmacol Ther2022-02-08T00:00:002022Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.35020832Kolkailah AA, Wiviott SD, Raz I, Murphy SA, Mosenzon O, Bhatt DL, Leiter LA, Wilding JPH, Gause-Nilsson I, Sabatine MS, McGuire DKDiabetes careEffect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58. Diabetes Care. 2022 02 01; 45(2):e27-e29.Diabetes Care2022-02-01T00:00:002022Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.35015847Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Sabatine MS, Raz IDiabetes careAssociation of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 2022 04 01; 45(4):938-946.Diabetes Care2022-04-01T00:00:002022Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58.Authorship 14247105Authorship 142588410Authorship 142618614Authorship 142739419Authorship 1428693335086664Oyama K, Giugliano RP, Sabatine MS, Cannon CP, Braunwald EJournal of the American College of CardiologyReply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 02 01; 79(4):e153.J Am Coll Cardiol2022-02-01T00:00:002022Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol.Authorship 1431437935115084Docherty KF, Simpson J, Jhund PS, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Sjöstrand M, Lindholm D, Langkilde AM, Solomon SD, McMurray JJVJACC. Heart failureEffect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC Heart Fail. 2022 02; 10(2):104-118.JACC Heart Fail2022-01-12T00:00:002022Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.true1Assistant Professor of MedicineAssistant Professor of MedicineAuthorship 14385251235209731Furtado RHM, Fagundes AA, Oyama K, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Wang H, Keech AC, Giugliano RP, Sabatine MS, Bergmark BACirculation. Cardiovascular interventionsEffect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011382.Circ Cardiovasc Interv2022-02-25T00:00:002022Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.Authorship 144503313Authorship 144601119Authorship 144706812Authorship 14497444Authorship 144889810Authorship 144615318Authorship 14474711335510542Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SDCirculationEfficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022 05 24; 145(21):1581-1591.Circulation2022-05-05T00:00:002022Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.35369705Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, Park JG, Murphy SA, Verma S, Wojakowski W, Terra SG, Sabatine MS, Wiviott SDCirculationEffect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022 05 03; 145(18):1377-1386.Circulation2022-04-03T00:00:002022Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.35483792Yeoh SE, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJVJACC. Heart failureRelationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial. JACC Heart Fail. 2022 05; 10(5):306-318.JACC Heart Fail2022-04-06T00:00:002022Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.35394821Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJLCirculationSodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation. 2022 05 10; 145(19):1460-1470.Circulation2022-04-08T00:00:002022Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.35404972Korthauer LE, Giugliano RP, Guo J, Sabatine MS, Sever P, Keech A, Atar D, Kurtz C, Ruff CT, Mach F, Ott BRPloS oneNo association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. PLoS One. 2022; 17(4):e0266615.PLoS One2022-04-11T00:00:002022No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab.35442064Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Petrie MC, Ponikowski P, Sabatine MS, Schou M, Solomon SD, Verma S, Bengtsson O, Langkilde AM, Sjöstrand M, Vaduganathan M, Jhund PS, McMurray JJVCirculationInitial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation. 2022 08 09; 146(6):438-449.Circulation2022-04-20T00:00:002022Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.35467935Butt JH, Dewan P, Merkely B, Belohlávek J, Drozdz J, Kitakaze M, Inzucchi SE, Kosiborod MN, Martinez FA, Tereshchenko S, Ponikowski P, Bengtsson O, Lindholm D, Langkilde AM, Schou M, Sjöstrand M, Solomon SD, Sabatine MS, Chiang CE, Docherty KF, Jhund PS, Køber L, McMurray JJVAnnals of internal medicineEfficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial. Ann Intern Med. 2022 06; 175(6):820-830.Ann Intern Med2022-04-26T00:00:002022Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.true1Professor of MedicineProfessor of MedicineAuthorship 1451035835588897O'Donoghue ML, G López JA, Knusel B, Gencer B, Wang H, Wu Y, Kassahun H, Sabatine MSAmerican heart journalStudy design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022 09; 251:61-69.Am Heart J2022-05-16T00:00:002022Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE).Authorship 34970236042188Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SANature communicationsEndophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Nat Commun. 2022 08 30; 13(1):5106.Nat Commun2022-08-30T00:00:002022Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes.Authorship 14593606Authorship 145944711Authorship 14641273Authorship 14593139Authorship 14633691535855557Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MPClinical cardiologyEpidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2022 Aug; 45(8):831-838.Clin Cardiol2022-07-19T00:00:002022Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.35760720Schludi B, Giugliano RP, Sabatine MS, Raal FJ, Teramoto T, Koren MJ, Stein EA, Wang H, Monsalvo MLJournal of clinical lipidologyTime-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. J Clin Lipidol. 2022 Jul-Aug; 16(4):538-543.J Clin Lipidol2022-06-06T00:00:002022Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.35902157Butt JH, Dewan P, DeFilippis EM, Biering-Sørensen T, Docherty KF, Jhund PS, Kosiborod MN, Martinez FA, Bengtsson O, Johansen ND, Langkilde AM, Sjöstrand M, Vaduganathan M, Solomon SD, Sabatine MS, Køber L, Fiuzat M, McMurray JJVJACC. Heart failureEffects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF. JACC Heart Fail. 2022 08; 10(8):543-555.JACC Heart Fail2022-06-08T00:00:002022Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.35715946Scirica BM, Im K, Murphy SA, Kuder JF, Rodriguez DA, Lopes RD, Green JB, Ruff CT, Sabatine MSClinical cardiologyRe-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. Clin Cardiol. 2022 Jul; 45(7):794-801.Clin Cardiol2022-06-17T00:00:002022Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.35857296Oyama K, Raz I, Cahn A, Goodrich EL, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Mosenzon O, Sabatine MS, Wiviott SDJAMA cardiologyEfficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022 09 01; 7(9):914-923.JAMA Cardiol2022-09-01T00:00:002022Efficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.36036760Bohula EA, Berg DD, Lopes MS, Connors JM, Babar I, Barnett CF, Chaudhry SP, Chopra A, Ginete W, Ieong MH, Katz JN, Kim EY, Kuder JF, Mazza E, McLean D, Mosier JM, Moskowitz A, Murphy SA, O'Donoghue ML, Park JG, Prasad R, Ruff CT, Shahrour MN, Sinha SS, Wiviott SD, Van Diepen S, Zainea M, Baird-Zars V, Sabatine MS, Morrow DACirculationAnticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. Circulation. 2022 Nov; 146(18):1344-1356.Circulation2022-08-29T00:00:002022Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.Authorship 164493Authorship 409265136342789Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ, Vardeny O, O'Meara E, Zieroth S, Katova T, McGrath MM, Pouleur AC, Jhund PS, Desai AS, Inzucchi SE, Kosiborod MN, de Boer RA, Kober L, Sabatine MS, Martinez FA, Ponikowski P, Shah SJ, Hernandez AF, Langkilde AM, McMurray JJV, Solomon SD, Lam CSPCirculationSex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. Circulation. 2023 02 21; 147(8):624-634.Circulation2022-11-07T00:00:002022Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.Authorship 14791832Authorship 149133920Authorship 148373813Authorship 149594619Authorship 149783029Authorship 149326516Authorship 149690221Authorship 149382721Authorship 150329916Authorship 149835526Authorship 1493730102Authorship 150334019Authorship 149337041Authorship 148801410Authorship 150190812Authorship 148446215Authorship 147867941Authorship 149739815Authorship 149779013Authorship 15032461535971840Docherty KF, Welsh P, Verma S, De Boer RA, O'Meara E, Bengtsson O, Køber L, Kosiborod MN, Hammarstedt A, Langkilde AM, Lindholm D, Little DJ, Sjöstrand M, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Schou M, Solomon SD, Sattar N, Jhund PS, McMurray JJVCirculationIron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation. 2022 Sep 27; 146(13):980-994.Circulation2022-08-16T00:00:002022Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.36339117Docherty KF, Anand IS, Chiang CE, Chopra VK, Desai AS, Kitakaze M, Verma S, Vinh PN, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Langkilde AM, Jhund PS, McMurray JJVJACC. AsiaEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia. 2022 Apr; 2(2):139-153.JACC Asia2022-03-29T00:00:002022Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.36007987Fagundes A, Morrow DA, Oyama K, Furtado RHM, Zelniker TA, Tang M, Kuder JF, Murphy SA, Hamer A, Keech AC, Sever P, Giugliano RP, Sabatine MS, Bergmark BAJournal of the American College of CardiologyBiomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. J Am Coll Cardiol. 2022 08 30; 80(9):887-897.J Am Coll Cardiol2022-08-30T00:00:002022Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.36180795Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, He Y, Georgakis MK, Caro I, Krebs K, Liaw YC, Vaura FC, Lin K, Winsvold BS, Srinivasasainagendra V, Parodi L, Bae HJ, Chauhan G, Chong MR, Tomppo L, Akinyemi R, Roshchupkin GV, Habib N, Jee YH, Thomassen JQ, Abedi V, Cárcel-Márquez J, Nygaard M, Leonard HL, Yang C, Yonova-Doing E, Knol MJ, Lewis AJ, Judy RL, Ago T, Amouyel P, Armstrong ND, Bakker MK, Bartz TM, Bennett DA, Bis JC, Bordes C, Børte S, Cain A, Ridker PM, Cho K, Chen Z, Cruchaga C, Cole JW, de Jager PL, de Cid R, Endres M, Ferreira LE, Geerlings MI, Gasca NC, Gudnason V, Hata J, He J, Heath AK, Ho YL, Havulinna AS, Hopewell JC, Hyacinth HI, Inouye M, Jacob MA, Jeon CE, Jern C, Kamouchi M, Keene KL, Kitazono T, Kittner SJ, Konuma T, Kumar A, Lacaze P, Launer LJ, Lee KJ, Lepik K, Li J, Li L, Manichaikul A, Markus HS, Marston NA, Meitinger T, Mitchell BD, Montellano FA, Morisaki T, Mosley TH, Nalls MA, Nordestgaard BG, O'Donnell MJ, Okada Y, Onland-Moret NC, Ovbiagele B, Peters A, Psaty BM, Rich SS, Rosand J, Sabatine MS, Sacco RL, Saleheen D, Sandset EC, Salomaa V, Sargurupremraj M, Sasaki M, Satizabal CL, Schmidt CO, Shimizu A, Smith NL, Sloane KL, Sutoh Y, Sun YV, Tanno K, Tiedt S, Tatlisumak T, Torres-Aguila NP, Tiwari HK, Trégouët DA, Trompet S, Tuladhar AM, Tybjærg-Hansen A, van Vugt M, Vibo R, Verma SS, Wiggins KL, Wennberg P, Woo D, Wilson PWF, Xu H, Yang Q, Yoon K, Millwood IY, Gieger C, Ninomiya T, Grabe HJ, Jukema JW, Rissanen IL, Strbian D, Kim YJ, Chen PH, Mayerhofer E, Howson JMM, Irvin MR, Adams H, Wassertheil-Smoller S, Christensen K, Ikram MA, Rundek T, Worrall BB, Lathrop GM, Riaz M, Simonsick EM, Kõrv J, França PHC, Zand R, Prasad K, Frikke-Schmidt R, de Leeuw FE, Liman T, Haeusler KG, Ruigrok YM, Heuschmann PU, Longstreth WT, Jung KJ, Bastarache L, Paré G, Damrauer SM, Chasman DI, Rotter JI, Anderson CD, Zwart JA, Niiranen TJ, Fornage M, Liaw YP, Seshadri S, Fernández-Cadenas I, Walters RG, Ruff CT, Owolabi MO, Huffman JE, Milani L, Kamatani Y, Dichgans M, Debette SNatureStroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022 11; 611(7934):115-123.Nature2022-09-30T00:00:002022Stroke genetics informs drug discovery and risk prediction across ancestries.36180445Halford JL, Morrill VN, Choi SH, Jurgens SJ, Melloni G, Marston NA, Weng LC, Nauffal V, Hall AW, Gunn S, Austin-Tse CA, Pirruccello JP, Khurshid S, Rehm HL, Benjamin EJ, Boerwinkle E, Brody JA, Correa A, Fornwalt BK, Gupta N, Haggerty CM, Harris S, Heckbert SR, Hong CC, Kooperberg C, Lin HJ, Loos RJF, Mitchell BD, Morrison AC, Post W, Psaty BM, Redline S, Rice KM, Rich SS, Rotter JI, Schnatz PF, Soliman EZ, Sotoodehnia N, Wong EK, Sabatine MS, Ruff CT, Lunetta KL, Ellinor PT, Lubitz SANature communicationsPublisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes. Nat Commun. 2022 Sep 30; 13(1):5767.Nat Commun2022-09-30T00:00:002022Publisher Correction: Endophenotype effect sizes support variant pathogenicity in monogenic disease susceptibility genes.36342163O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MSThe New England journal of medicineSmall Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 11 17; 387(20):1855-1864.N Engl J Med2022-11-06T00:00:002022Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.35921092Natarajan P, Sabatine MSJAMA cardiologyAnticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP. JAMA Cardiol. 2022 09 01; 7(9):964-965.JAMA Cardiol2022-09-01T00:00:002022Anticipating Pharmacological Perturbation With Human Genetic Variation-Lessons From CETP.35997319Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine MSDiabetes careDapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care. 2022 10 01; 45(10):2350-2359.Diabetes Care2022-10-01T00:00:002022Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.36030328Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, Vaduganathan M, Gasparyan SB, Bengtsson O, Lindholm D, Petersson M, Langkilde AM, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Sabatine MS, Shah SJ, Solomon SD, McMurray JJVNature medicineDapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022 09; 28(9):1956-1964.Nat Med2022-08-27T00:00:002022Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.36074222McCoy MG, Jamaiyar A, Sausen G, Cheng HS, Pérez-Cremades D, Zhuang R, Chen J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MWAngiogenesisMicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. Angiogenesis. 2023 02; 26(1):107-127.Angiogenesis2022-09-08T00:00:002022MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia.36367709Bonaca MP, Im K, Magnani G, Bansilal S, Dellborg M, Storey RF, Bhatt DL, Steg PG, Cohen M, Johanson P, Braunwald E, Sabatine MSEuropean heart journalPatient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. Eur Heart J. 2022 Nov 11.Eur Heart J2022-11-11T00:00:002022Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54.36017729Kondo T, Abdul-Rahim AH, Talebi A, Abraham WT, Desai AS, Dickstein K, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Packer M, Petrie M, Ponikowski P, Rouleau JL, Sabatine MS, Swedberg K, Zile MR, Solomon SD, Jhund PS, McMurray JJVEuropean heart journalPredicting stroke in heart failure and reduced ejection fraction without atrial fibrillation. Eur Heart J. 2022 11 07; 43(42):4469-4479.Eur Heart J2022-11-07T00:00:002022Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.36303404Kato ET, Morrow DA, Guo J, Berg DD, Blazing MA, Bohula EA, Bonaca MP, Cannon CP, de Lemos JA, Giugliano RP, Jarolim P, Kempf T, Kristin Newby L, O'Donoghue ML, Pfeffer MA, Rifai N, Wiviott SD, Wollert KC, Braunwald E, Sabatine MSEuropean heart journalGrowth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023 01 21; 44(4):293-300.Eur Heart J2023-01-21T00:00:002023Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.36039762Bonaca MP, Morrow DA, Bergmark BA, Berg DD, Lima JAC, Hoffmann U, Kato Y, Lu MT, Kuder J, Murphy SA, Spinar J, Oude Ophuis T, Kiss RG, Lopez-Sendon J, Averkov O, Wheatcroft SB, Kubica J, Carlos Nicolau J, Furtado RHM, Abuhatzira L, Hirshberg B, Omar SA, Vavere AL, Chang YT, George RT, Sabatine MSCirculationRandomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Circulation. 2022 Sep 20; 146(12):907-916.Circulation2022-08-30T00:00:002022Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.36054568Adamson C, Cowan LM, de Boer RA, Diez M, Drozdz J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Lindholm D, Bengtsson O, Boulton DW, Greasley PJ, Langkilde AM, Sjöstrand M, Solomon SD, McMurray JJV, Jhund PSEuropean journal of heart failureLiver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. Eur J Heart Fail. 2022 10; 24(10):1856-1868.Eur J Heart Fail2022-08-22T00:00:002022Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.36031810O'Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, Im K, Murphy SA, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Sabatine MSCirculationLong-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 10 11; 146(15):1109-1119.Circulation2022-08-29T00:00:002022Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.35980763Marston NA, Garfinkel AC, Kamanu FK, Melloni GM, Roselli C, Jarolim P, Berg DD, Bhatt DL, Bonaca MP, Cannon CP, Giugliano RP, O'Donoghue ML, Raz I, Scirica BM, Braunwald E, Morrow DA, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CTEuropean heart journalA polygenic risk score predicts atrial fibrillation in cardiovascular disease. Eur Heart J. 2023 01 14; 44(3):221-231.Eur Heart J2023-01-14T00:00:002023A polygenic risk score predicts atrial fibrillation in cardiovascular disease.Authorship 1504792102Authorship 15045911536376532Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, Le Grand Q, Shi M, He Y, Georgakis MK, Caro I, Krebs K, Liaw YC, Vaura FC, Lin K, Winsvold BS, Srinivasasainagendra V, Parodi L, Bae HJ, Chauhan G, Chong MR, Tomppo L, Akinyemi R, Roshchupkin GV, Habib N, Jee YH, Thomassen JQ, Abedi V, Cárcel-Márquez J, Nygaard M, Leonard HL, Yang C, Yonova-Doing E, Knol MJ, Lewis AJ, Judy RL, Ago T, Amouyel P, Armstrong ND, Bakker MK, Bartz TM, Bennett DA, Bis JC, Bordes C, Børte S, Cain A, Ridker PM, Cho K, Chen Z, Cruchaga C, Cole JW, de Jager PL, de Cid R, Endres M, Ferreira LE, Geerlings MI, Gasca NC, Gudnason V, Hata J, He J, Heath AK, Ho YL, Havulinna AS, Hopewell JC, Hyacinth HI, Inouye M, Jacob MA, Jeon CE, Jern C, Kamouchi M, Keene KL, Kitazono T, Kittner SJ, Konuma T, Kumar A, Lacaze P, Launer LJ, Lee KJ, Lepik K, Li J, Li L, Manichaikul A, Markus HS, Marston NA, Meitinger T, Mitchell BD, Montellano FA, Morisaki T, Mosley TH, Nalls MA, Nordestgaard BG, O'Donnell MJ, Okada Y, Onland-Moret NC, Ovbiagele B, Peters A, Psaty BM, Rich SS, Rosand J, Sabatine MS, Sacco RL, Saleheen D, Sandset EC, Salomaa V, Sargurupremraj M, Sasaki M, Satizabal CL, Schmidt CO, Shimizu A, Smith NL, Sloane KL, Sutoh Y, Sun YV, Tanno K, Tiedt S, Tatlisumak T, Torres-Aguila NP, Tiwari HK, Trégouët DA, Trompet S, Tuladhar AM, Tybjærg-Hansen A, van Vugt M, Vibo R, Verma SS, Wiggins KL, Wennberg P, Woo D, Wilson PWF, Xu H, Yang Q, Yoon K, Millwood IY, Gieger C, Ninomiya T, Grabe HJ, Jukema JW, Rissanen IL, Strbian D, Kim YJ, Chen PH, Mayerhofer E, Howson JMM, Irvin MR, Adams H, Wassertheil-Smoller S, Christensen K, Ikram MA, Rundek T, Worrall BB, Lathrop GM, Riaz M, Simonsick EM, Kõrv J, França PHC, Zand R, Prasad K, Frikke-Schmidt R, de Leeuw FE, Liman T, Haeusler KG, Ruigrok YM, Heuschmann PU, Longstreth WT, Jung KJ, Bastarache L, Paré G, Damrauer SM, Chasman DI, Rotter JI, Anderson CD, Zwart JA, Niiranen TJ, Fornage M, Liaw YP, Seshadri S, Fernández-Cadenas I, Walters RG, Ruff CT, Owolabi MO, Huffman JE, Milani L, Kamatani Y, Dichgans M, Debette SNaturePublisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022 Dec; 612(7938):E7.Nature2022-12-01T00:00:002022Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries.36399721Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn ADiabetes careEfficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. Diabetes Care. 2023 01 01; 46(1):156-164.Diabetes Care2023-01-01T00:00:002023Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.Authorship 150870812Authorship 15093747936474045Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM, Sherliker P, Koyama S, Ishigaki K, Åsvold BO, Brown MR, Brumpton B, de Vries PS, Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Güldener U, Haider SMI, Helgadottir A, Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S, Munz M, Murgia F, Nielsen JB, Nöthen MM, Pang S, Reinberger T, Schnitzler G, Smedley D, Thorleifsson G, von Scheidt M, Ulirsch JC, Arnar DO, Burtt NP, Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Björkegren JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT, Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J, Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth ASNature geneticsDiscovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022 12; 54(12):1803-1815.Nat Genet2022-12-06T00:00:002022Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants.36493607Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta SR, Pollack CV, Sabate M, Rao SV, Parkhomenko A, Feldman LJ, Sayah N, Sabatine MS, Steg PGThe American journal of cardiologyClinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Am J Cardiol. 2023 02 01; 188:95-101.Am J Cardiol2022-12-06T00:00:002022Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention.Authorship 151364914Authorship 15128351536576811Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, Roselli C, Kamatani Y, Komuro I, Aragam KG, Butterworth AS, Ito K, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CTJAMA cardiologyPredictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. JAMA Cardiol. 2023 02 01; 8(2):130-137.JAMA Cardiol2023-02-01T00:00:002023Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.36592046Adamson C, Welsh P, Docherty KF, de Boer RA, Diez M, Drozdz J, Dukát A, Inzucchi SE, Køber L, Kosiborod MN, Ljungman CEA, Martinez FA, Ponikowski P, Sabatine MS, Morrow DA, Lindholm D, Hammarstedt A, Boulton DW, Greasley PJ, Langkilde AM, Solomon SD, Sattar N, McMurray JJV, Jhund PSJACC. Heart failureIGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2023 03; 11(3):291-304.JACC Heart Fail2022-11-09T00:00:002022IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.Authorship 1518373636691960Freedman BL, Berg DD, Scirica BM, Bohula EA, Goodrich EL, Sabatine MS, Morrow DA, Bonaca MPClinical cardiologyResponse to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. Clin Cardiol. 2023 03; 46(3):348-349.Clin Cardiol2023-01-24T00:00:002023Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial.Authorship 15214225Authorship 15223581136713994Rousset A, Dellamonica D, Menuet R, Lira Pineda A, Sabatine MS, Giugliano RP, Trichelair P, Zaslavskiy M, Ricci LEuropean heart journal. Digital healthCan machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. Eur Heart J Digit Health. 2022 Mar; 3(1):38-48.Eur Heart J Digit Health2021-11-15T00:00:002021Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data.36720377Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RFVascular pharmacologyInfluence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascul Pharmacol. 2023 04; 149:107145.Vascul Pharmacol2023-01-28T00:00:002023Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.Authorship 152695815Authorship 152374123Authorship 15271011336821386Cheng HS, Zhuang R, Pérez-Cremades D, Chen J, Jamaiyar A, Wu W, Sausen G, Tzani A, Plutzky J, Henao-Mejia J, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MWJCI insightA miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. JCI Insight. 2023 04 10; 8(7).JCI Insight2023-04-10T00:00:002023A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia.36811901Butt JH, Docherty KF, Claggett BL, Desai AS, Petersson M, Langkilde AM, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJVJAMA cardiologyAssociation of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2023 04 01; 8(4):386-393.JAMA Cardiol2023-04-01T00:00:002023Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.36779348Gaba P, O'Donoghue ML, Park JG, Wiviott SD, Atar D, Kuder JF, Im K, Murphy SA, De Ferrari GM, Gaciong ZA, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Flores-Arredondo JH, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Abbasi S, Giugliano RP, Sabatine MSCirculationAssociation Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023 04 18; 147(16):1192-1203.Circulation2023-02-13T00:00:002023Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.Authorship 15291051936857035Zelniker TA, Wiviott SD, Mosenzon O, Goodrich EL, Jarolim P, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding J, Averkov O, Budaj A, Parkhomenko A, Ray KK, Gause-Nilsson I, Langkilde AM, Fredriksson M, Raz I, Sabatine MS, Morrow DAJAMA cardiologyAssociation of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. JAMA Cardiol. 2023 05 01; 8(5):503-509.JAMA Cardiol2023-05-01T00:00:002023Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.Authorship 153186218Authorship 15319941736881399Butt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Vardeny O, O'Meara E, Saraiva JFK, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJVJACC. Heart failureDapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. JACC Heart Fail. 2023 04; 11(4):375-388.JACC Heart Fail2023-02-01T00:00:002023Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.36878239Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, Murphy SA, Zelniker TA, Fredriksson M, Johansson PA, Leiter LA, Bhatt DL, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Cahn A, Langkilde AM, Sabatine MS, Mosenzon OThe lancet. Diabetes & endocrinologyEffects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023 04; 11(4):233-241.Lancet Diabetes Endocrinol2023-03-03T00:00:002023Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.Authorship 1987702Authorship 2124455Authorship 483940837344040Berg DD, Moura FA, Bellavia A, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Bohula EA, Giugliano RP, Park JG, Feinberg MW, Braunwald E, Morrow DA, Sabatine MSJournal of the American College of CardiologyAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2023 06 27; 81(25):2391-2402.J Am Coll Cardiol2023-06-27T00:00:002023Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus.Authorship 155218913Authorship 15657183Authorship 157080710Authorship 156656517Authorship 156507411Authorship 157352614Authorship 156091718Authorship 156400214Authorship 15681351337256598Gaba P, Christiansen EH, Nielsen PH, Murphy SA, O'Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Stone GW, Sabik JF, Sabatine MS, Holm NR, Bergmark BAJAMA cardiologyPercutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials. JAMA Cardiol. 2023 07 01; 8(7):631-639.JAMA Cardiol2023-07-01T00:00:002023Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials.37068132O'Donoghue ML, Giugliano RP, Sabatine MSCirculationResponse by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease". Circulation. 2023 04 18; 147(16):1258-1259.Circulation2023-04-17T00:00:002023Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease".37318419Butt JH, Docherty KF, Kosiborod MN, Inzucchi SE, Køber L, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon S, Jhund PS, McMurray JJVJACC. Heart failureDapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2023 10; 11(10):1411-1423.JACC Heart Fail2023-06-14T00:00:002023Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction.37039015Yeoh SE, Docherty KF, Campbell RT, Jhund PS, Hammarstedt A, Heerspink HJL, Jarolim P, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Solomon SD, Sjöstrand M, Bengtsson O, Greasley PJ, Sattar N, Welsh P, Sabatine MS, Morrow DA, McMurray JJVCirculationEndothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. Circulation. 2023 05 30; 147(22):1670-1683.Circulation2023-04-11T00:00:002023Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.37407113Docherty KF, McDowell K, Welsh P, Osmanska J, Anand I, de Boer RA, Køber L, Kosiborod MN, Martinez FA, O'Meara E, Ponikowski P, Schou M, Berg DD, Sabatine MS, Morrow DA, Jarolim P, Hammarstedt A, Sjöstrand M, Langkilde AM, Solomon SD, Sattar N, Jhund PS, McMurray JJVJournal of the American College of CardiologyAssociation of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. 2023 07 11; 82(2):142-157.J Am Coll Cardiol2023-07-11T00:00:002023Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure.37097749Cheng HS, Pérez-Cremades D, Zhuang R, Jamaiyar A, Wu W, Chen J, Tzani A, Stone L, Plutzky J, Ryan TE, Goodney PP, Creager MA, Sabatine MS, Bonaca MP, Feinberg MWJCI insightImpaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis. JCI Insight. 2023 05 22; 8(10).JCI Insight2023-05-22T00:00:002023Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis.37358785Yang M, Kondo T, Butt JH, Abraham WT, Anand IS, Desai AS, Køber L, Packer M, Pfeffer MA, Rouleau JL, Sabatine MS, Solomon SD, Swedberg K, Zile MR, Jhund PS, McMurray JJVEuropean heart journalStroke in patients with heart failure and reduced or preserved ejection fraction. Eur Heart J. 2023 08 14; 44(31):2998-3013.Eur Heart J2023-08-14T00:00:002023Stroke in patients with heart failure and reduced or preserved ejection fraction.37220172Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Shah SJ, Zaozerska N, Wilderäng U, Bengtsson O, Solomon SD, McMurray JJVEuropean heart journalHeart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023 06 25; 44(24):2170-2183.Eur Heart J2023-06-25T00:00:002023Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER.37556796Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine MSDiabetes careRisk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2023 10 01; 46(10):1807-1815.Diabetes Care2023-10-01T00:00:002023Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.37610398Kondo T, Wang X, Yang M, Jhund PS, Claggett BL, Vaduganathan M, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Langkilde AM, Petersson M, Zaozerska N, Bachus E, Solomon SD, McMurray JJVJournal of the American College of CardiologyEfficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. J Am Coll Cardiol. 2023 09 05; 82(10):1014-1026.J Am Coll Cardiol2023-08-21T00:00:002023Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.Authorship 3221071Authorship 3515623Authorship 158525216Authorship 158239415Authorship 158409713Authorship 15859531437634707Chatur S, Vaduganathan M, Claggett BL, Mc Causland FR, Desai AS, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Sabatine MS, Kober L, Ponikowski P, Merkely B, Petersson M, Langkilde AM, McMurray JJV, Solomon SDJournal of the American College of CardiologyDapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. J Am Coll Cardiol. 2023 11 07; 82(19):1854-1863.J Am Coll Cardiol2023-08-25T00:00:002023Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function.37606673Helgason H, Eiriksdottir T, Ulfarsson MO, Choudhary A, Lund SH, Ivarsdottir EV, Hjorleifsson Eldjarn G, Einarsson G, Ferkingstad E, Moore KHS, Honarpour N, Liu T, Wang H, Hucko T, Sabatine MS, Morrow DA, Giugliano RP, Ostrowski SR, Pedersen OB, Bundgaard H, Erikstrup C, Arnar DO, Thorgeirsson G, Masson G, Magnusson OT, Saemundsdottir J, Gretarsdottir S, Steinthorsdottir V, Thorleifsson G, Helgadottir A, Sulem P, Thorsteinsdottir U, Holm H, Gudbjartsson D, Stefansson KJAMAEvaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. JAMA. 2023 08 22; 330(8):725-735.JAMA2023-08-22T00:00:002023Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.true1Hersey Distinguished Professor of the Theory and Practice of PhysicHersey Distinguished Professor of the Theory and Practice of Physictrue1Visiting Professor of MedicineVisiting Professor of MedicineAuthorship 160104418Authorship 1599138237913509Kaur G, Sabatine MS, Schaefer IM, Sun YP, Loscalzo JThe New England journal of medicineEncased in Peril. N Engl J Med. 2023 Nov 02; 389(18):1709-1716.N Engl J Med2023-11-02T00:00:002023Encased in Peril.37886880Kondo T, Butt JH, Curtain JP, Jhund PS, Docherty KF, Claggett BL, Vaduganathan M, Bachus E, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Solomon SD, McMurray JJVCirculation. Heart failureEfficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. Circ Heart Fail. 2023 Dec; 16(12):e010898.Circ Heart Fail2023-10-27T00:00:002023Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.38106527Patel SM, Bonaca MP, Morrow DA, Palazzolo MG, Jarolim P, Steg PG, Bhatt DL, Storey RF, Sabatine MS, O'Donoghue MLJACC. AdvancesLipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial. JACC Adv. 2023 Nov; 2(9).JACC Adv2023-10-28T00:00:002023Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.Authorship 161402414Authorship 16141189Authorship 16149011238104937Butt JH, Jering K, DE Boer RA, Claggett BL, Desai AS, Hernandez AF, Inzucchi SE, Jhund PS, Køber L, Kosiborod MN, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Shah SJ, Vaduganathan M, Langkilde AM, Bengtsson O, Petersson M, Sjöstrand M, Wilderäng U, Solomon SD, McMurray JJVJournal of cardiac failureHeart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER. J Card Fail. 2023 Dec 15.J Card Fail2023-12-15T00:00:002023Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.38131261Patel SM, Morrow DA, Bellavia A, Berg DD, Bhatt DL, Jarolim P, Leiter LA, McGuire DK, Raz I, Steg PG, Wilding JPH, Sabatine MS, Wiviott SD, Braunwald E, Scirica BM, Bohula EAEuropean journal of heart failureNatriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61. Eur J Heart Fail. 2023 Dec 22.Eur J Heart Fail2023-12-22T00:00:002023Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.Authorship 161776312Authorship 16176771438160917Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MSAmerican heart journalRationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. Am Heart J. 2024 Mar; 269:179-190.Am Heart J2023-12-29T00:00:002023Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.38158248Zimerman A, Wiviott SD, Park JG, Murphy SA, Ran X, Bramson CR, Curto M, Ramos V, Jevne A, Kuder JF, Verma S, Wojakowski W, Terra SG, Sabatine MS, Bergmark BA, Marston NAJournal of clinical lipidologyHepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3. J Clin Lipidol. 2023 Dec 10.J Clin Lipidol2023-12-10T00:00:002023Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3.Authorship 1621596838233021Marston NA, Melloni GEM, Murphy SA, Morze J, Kamanu FK, Ellinor PT, Ruff CT, Sabatine MSJournal of the American College of CardiologyPer-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins. J Am Coll Cardiol. 2024 Jan 23; 83(3):470-472.J Am Coll Cardiol2024-01-23T00:00:002024Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins.Authorship 5695592Authorship 162787814Authorship 16275341638325990McClintick DJ, O'Donoghue ML, De Ferrari GM, Ferreira J, Ran X, Im K, López JAG, Elliott-Davey M, Wang B, Monsalvo ML, Atar D, Keech A, Giugliano RP, Sabatine MSJournal of the American College of CardiologyLong-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease. J Am Coll Cardiol. 2024 Feb 13; 83(6):652-664.J Am Coll Cardiol2024-02-13T00:00:002024Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease.38320525Kondo T, Gasparyan SB, Jhund PS, Bengtsson O, Claggett BL, de Boer RA, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Langkilde AM, Martinez FA, Petersson M, Ponikowski P, Sabatine MS, Shah SJ, Sjostrand M, Wilderang U, Vaduganathan M, Solomon SD, McMurray JJVNEJM evidenceUse of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials. NEJM Evid. 2023 Nov; 2(11):EVIDoa2300042.NEJM Evid2023-10-24T00:00:002023Use of Win Statistics to Analyze Outcomes in the DAPA-HF and DELIVER Trials.Authorship 1782511Authorship 1800982Authorship 162984822Authorship 163323411Authorship 1632166199Authorship 162911018Authorship 1631335938373851Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B, Armitage J, Baigent C, Barnes E, Blackwell L, Collins R, Davies K, Emberson J, Fulcher J, Halls H, Herrington WG, Holland L, Keech A, Kirby A, Mihaylova B, O'Connell R, Preiss D, Reith C, Simes J, Wilson K, Blazing M, Braunwald E, Lemos J, Murphy S, Pedersen TR, Pfeffer M, White H, Wiviott S, Clearfield M, Downs JR, Gotto A, Weis S, Fellström B, Holdaas H, Jardine A, Pedersen TR, Gordon D, Davis B, Furberg C, Grimm R, Pressel S, Probstfield JL, Rahman M, Simpson L, Koren M, Dahlöf B, Gupta A, Poulter N, Sever P, Wedel H, Knopp RH, Cobbe S, Fellström B, Holdaas H, Jardine A, Schmieder R, Zannad F, Betteridge DJ, Colhoun HM, Durrington PN, Fuller J, Hitman GA, Neil A, Braunwald E, Davis B, Hawkins CM, Moyé L, Pfeffer M, Sacks F, Kjekshus J, Wedel H, Wikstrand J, Wanner C, Krane V, Franzosi MG, Latini R, Lucci D, Maggioni A, Marchioli R, Nicolis EB, Tavazzi L, Tognoni G, Bosch J, Lonn E, Yusuf S, Armitage J, Bowman L, Collins R, Keech A, Landray M, Parish S, Peto R, Sleight P, Kastelein JJ, Pedersen TR, Glynn R, Gotto A, Kastelein JJ, Koenig W, MacFadyen J, Ridker PM, Keech A, MacMahon S, Marschner I, Tonkin A, Shaw J, Simes J, White H, Serruys PW, Knatterud G, Blauw GJ, Cobbe S, Ford I, Macfarlane P, Packard C, Sattar N, Shepherd J, Trompet S, Braunwald E, Cannon CP, Murphy S, Collins R, Armitage J, Bowman L, Bulbulia R, Haynes R, Parish S, Peto R, Sleight P, Amarenco P, Welch KM, Kjekshus J, Pedersen TR, Wilhelmsen L, Barter P, Gotto A, LaRosa J, Kastelein JJ, Shepherd J, Cobbe S, Ford I, Kean S, Macfarlane P, Packard C, Roberston M, Sattar N, Shepherd J, Young R, Arashi H, Clarke R, Flather M, Goto S, Goldbourt U, Hopewell J, Hovingh GK, Kitas G, Newman C, Sabatine MS, Schwartz GG, Smeeth L, Tobert J, Varigos J, Yamamguchi JThe British journal of general practice : the journal of the Royal College of General PractitionersLong-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model. Br J Gen Pract. 2024 Feb 19.Br J Gen Pract2024-02-19T00:00:002024Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.38428421Chen J, Jamaiyar A, Wu W, Hu Y, Zhuang R, Sausen G, Cheng HS, de Oliveira Vaz C, Pérez-Cremades D, Tzani A, McCoy MG, Assa C, Eley S, Randhawa V, Lee K, Plutzky J, Hamburg NM, Sabatine MS, Feinberg MWCell reportsDeficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis. Cell Rep. 2024 Feb 26; 113815.Cell Rep2024-02-26T00:00:002024Deficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis.38416462Small AM, Melloni GEM, Kamanu FK, Bergmark BA, Bonaca MP, O'Donoghue ML, Giugliano RP, Scirica BM, Bhatt D, Antman EM, Raz I, Wiviott SD, Truong B, Wilson PWF, Cho K, O'Donnell CJ, Braunwald E, Lubitz SA, Ellinor P, Peloso GM, Ruff CT, Sabatine MS, Natarajan P, Marston NAJAMA cardiologyNovel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis. JAMA Cardiol. 2024 Feb 28.JAMA Cardiol2024-02-28T00:00:002024Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis.38390793Bhatt AS, Vaduganathan M, Claggett BL, Kulac IJ, Anand IS, Desai AS, Fang JC, Hernandez AF, Jhund PS, Kosiborod MN, Sabatine MS, Shah SJ, Vardeny O, McMurray JJV, Solomon SD, Gaziano TAJournal of the American Heart AssociationCost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials. J Am Heart Assoc. 2024 Mar 05; 13(5):e032279.J Am Heart Assoc2024-02-23T00:00:002024Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.38353970Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, Braunwald E, Giugliano RP, Sabatine MS, Peloso GM, Marston NA, Natarajan PJAMA cardiologyLipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiol. 2024 Feb 14.JAMA Cardiol2024-02-14T00:00:002024Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.Authorship 582205Authorship 586628Authorship 2456407Authorship 29633310Authorship 4278931Authorship 4442371Authorship 3110153Authorship 494099153Authorship 598765Authorship 614289Authorship 364229Authorship 665983Authorship 877268Authorship 19892211Authorship 5062762Authorship 580582Authorship 588448Authorship 227231Authorship 6737198Authorship 67546435Authorship 6761751223884353Desai NR, Kohli P, Giugliano RP, O'Donoghue ML, Somaratne R, Zhou J, Hoffman EB, Huang F, Rogers WJ, Wasserman SM, Scott R, Sabatine MSCirculationAMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013 Aug 27; 128(9):962-9.Circulation2013-07-24T00:00:002013AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.23995608Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim JH, Jeong MH, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MSJAMAAnticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA. 2013 Sep 18; 310(11):1145-55.JAMA2013-09-18T00:00:002013Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.23698643Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner ARClinical pharmacology and therapeuticsClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep; 94(3):317-23.Clin Pharmacol Ther2013-05-22T00:00:002013Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Authorship 689336324147518Bansilal S, Bonaca MP, Sabatine MSExpert review of cardiovascular therapyTicagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013 Nov; 11(11):1473-84.Expert Rev Cardiovasc Ther2013-10-23T00:00:002013Ticagrelor for acute coronary syndromes.Authorship 6918996Authorship 692295110Authorship 692633523916927Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van 't Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KAA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Paré G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJJournal of the American College of CardiologySecretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19; 62(21):1966-1976.J Am Coll Cardiol2013-07-31T00:00:002013Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.24222830Bonaca MP, Ruff CT, Kosowsky J, Conrad MJ, Murphy SA, Sabatine MS, Jarolim P, Morrow DAEuropean heart journal. Acute cardiovascular careEvaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):195-202.Eur Heart J Acute Cardiovasc Care2013-09-01T00:00:002013Evaluation of the diagnostic performance of current and next-generation assays for cardiac troponin I in the BWH-TIMI ED Chest Pain Study.24064010Mogabgab O, Wiviott SD, Cannon CP, Sloan S, Sabatine MS, Antman EM, Braunwald E, Giugliano RPJournal of cardiovascular pharmacology and therapeuticsCircadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.J Cardiovasc Pharmacol Ther2013-09-24T00:00:002013Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.Authorship 694532524268219Desai NR, Peterson ED, Chen AY, Wiviott SD, Sabatine MS, Alexander KP, Roe MT, Shah BRAmerican heart journalBalancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. Am Heart J. 2013 Dec; 166(6):1043-1049.e1.Am Heart J2013-10-11T00:00:002013Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry.Authorship 1797592Authorship 2268371Authorship 698428824239201Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue MLJACC. Cardiovascular interventionsConcomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 2013 Dec; 6(12):1275-81.JACC Cardiovasc Interv2013-11-13T00:00:002013Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).Authorship 2130974Authorship 700120824052087Bohula May EA, Bonaca MP, Jarolim P, Antman EM, Braunwald E, Giugliano RP, Newby LK, Sabatine MS, Morrow DAClinical chemistryPrognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. Clin Chem. 2014 Jan; 60(1):158-64.Clin Chem2013-09-19T00:00:002013Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome.24452727Waks JW, Sabatine MS, Cannon CP, Morrow DA, Gibson CM, Wiviott SD, Giugliano RP, Sloan S, Scirica BMClinical cardiologyClinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.Clin Cardiol2014-01-22T00:00:002014Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.Authorship 7040421324255061Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R, Wasserman SM, Sabatine MSCirculationEfficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014 Jan 14; 129(2):234-43.Circulation2013-11-19T00:00:002013Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.Authorship 2452011Authorship 2706902Authorship 272063624452775Sukul D, Bonaca MP, Ruff CT, Kosowsky J, Conrad M, Murphy SA, Sabatine MS, Jarolim P, Morrow DAClinical cardiologyDiagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study. Clin Cardiol. 2014 Apr; 37(4):227-32.Clin Cardiol2014-01-22T00:00:002014Diagnostic performance of copeptin in patients with acute nontraumatic chest pain: BWH-TIMI ED chest pain study.Authorship 404393Authorship 4081165Authorship 4293583Authorship 46884010Authorship 7245147Authorship 7228192Authorship 72075110Authorship 7238805Authorship 71805214Authorship 7182769Authorship 723782324161333Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MSJournal of the American College of CardiologyAMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol. 2014 Feb 11; 63(5):430-3.J Am Coll Cardiol2013-10-23T00:00:002013AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).24655690Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MSAmerican heart journalDesign and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014 Apr; 167(4):437-444.e5.Am Heart J2014-01-06T00:00:002014Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.24509273Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EAJournal of the American College of CardiologyReduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014 Apr 08; 63(13):1278-1288.J Am Coll Cardiol2014-02-05T00:00:002014Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.24161323O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MSJournal of the American College of CardiologyLipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014 Feb 18; 63(6):520-7.J Am Coll Cardiol2013-10-23T00:00:002013Lipoprotein(a) for risk assessment in patients with established coronary artery disease.24315920Holmes MV, Simon T, Exeter HJ, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJJournal of the American College of CardiologyReply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. J Am Coll Cardiol. 2014 Mar 11; 63(9):943.J Am Coll Cardiol2013-12-04T00:00:002013Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease.Authorship 2721723Authorship 2111102Authorship 7265246Authorship 728658824786143Sarma A, Cannon CP, de Lemos J, Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue MLJournal of the American Heart AssociationThe incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome. J Am Heart Assoc. 2014 May 01; 3(3):e000784.J Am Heart Assoc2014-05-01T00:00:002014The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.24530676O'Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, Braunwald E, Morrow DAJournal of the American College of CardiologyPrognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol. 2014 Apr 29; 63(16):1644-53.J Am Coll Cardiol2014-02-13T00:00:002014Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).24932507Turer AT, Lewis GD, O'Sullivan JF, Elmariah S, Mega JL, Addo TA, Sabatine MS, de Lemos JA, Gerszten REPloS oneIncreases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PLoS One. 2014; 9(6):e99058.PLoS One2014-06-16T00:00:002014Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism.Authorship 73687112Authorship 736515724727254Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O'Donnell TF, Vora AN, Omland T, Solomon SD, Pfeffer MA, Braunwald E, Sabatine MSJournal of the American College of CardiologyFibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. 2014 Jun 10; 63(22):2421-8.J Am Coll Cardiol2014-04-09T00:00:002014Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.Authorship 2889058Authorship 3168443Authorship 34506710Authorship 3643593Authorship 416163167Authorship 4287665Authorship 2717342Authorship 34995412Authorship 3890994Authorship 7473892Authorship 7512531225060370Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, Michelson AD, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JLJournal of the American College of CardiologyVariability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8.J Am Coll Cardiol2014-07-29T00:00:002014Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial.25131979Cavender MA, Sabatine MSLancet (London, England)Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014 Aug 16; 384(9943):599-606.Lancet2014-08-16T00:00:002014Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.Authorship 7545281524598985Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MSEuropean heart journalEfficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.Eur Heart J2014-03-04T00:00:002014Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.Authorship 605468Authorship 21334417Authorship 351864725359163Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine MS, Cheng S, Valcour A, Swales H, Taylor B, Carney E, Guanaga D, Young JR, Karol C, Torre M, Azzahir A, Strachan SM, O'Neill DC, Wolf M, Harrell F, Newton-Cheh C, Wang TJCirculationVitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015 Jan 20; 131(3):254-62.Circulation2014-10-30T00:00:002014Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial.Authorship 4700636Authorship 769773225399267Mega JL, Sabatine MS, Antman EMJAMAPopulation and personalized medicine in the modern era. JAMA. 2014 Nov 19; 312(19):1969-70.JAMA2014-11-19T00:00:002014Population and personalized medicine in the modern era.Authorship 4582375Authorship 77533515Authorship 7756261525260718Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJJournal of the American College of Cardiology2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23; 64(24):e139-e228.J Am Coll Cardiol2014-09-23T00:00:0020142014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.25260717Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJJournal of the American College of Cardiology2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23; 64(24):2645-87.J Am Coll Cardiol2014-09-23T00:00:0020142014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Authorship 77715115Authorship 7771521525249585Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJCirculation2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23; 130(25):e344-426.Circulation2014-09-23T00:00:0020142014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.25249586Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJCirculation2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23; 130(25):2354-94.Circulation2014-09-23T00:00:0020142014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Authorship 5745964Authorship 587111Authorship 588768Authorship 590581Authorship 5397626Authorship 600538Authorship 803622Authorship 3184861Authorship 591503Authorship 597120Authorship 5624514Authorship 626640Authorship 72061Authorship 613089Authorship 5096953Authorship 5734803Authorship 601098Authorship 614449Authorship 578932Authorship 4207382Authorship 610237Authorship 610488Authorship 977688Authorship 5486469Authorship 46516010Authorship 4803324Authorship 4961413Authorship 5457251Authorship 1765188Authorship 612820Authorship 597988Authorship 598063Authorship 876434Authorship 667346Authorship 915965Authorship 2803551Authorship 3339549Authorship 3438161Authorship 4183407Authorship 2546131Authorship 3495731Authorship 3428201Authorship 2051143Authorship 5274767Authorship 26234021Authorship 590241Authorship 600874Authorship 615185Authorship 620533Authorship 2687531Authorship 2981233Authorship 135271Authorship 29890511Authorship 3214641Authorship 4052471Authorship 4789321Authorship 54939110Authorship 5678245Authorship 40464111Authorship 2546166Authorship 33820825Authorship 361783Authorship 41207310Authorship 5004401Authorship 5284066Authorship 7896945Authorship 8039581Authorship 8029651Authorship 80436911Authorship 79280825Authorship 8049011025965709O'Donoghue ML, Glaser R, Aylward PE, Cavender MA, Crisp A, Fox KA, Laws I, Lopez-Sendon JL, Steg PG, Theroux P, Sabatine MS, Morrow DAAmerican heart journalRationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. Am Heart J. 2015 May; 169(5):622-630.e6.Am Heart J2015-02-23T00:00:002015Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial.25737394Grinstein J, Bonaca MP, Jarolim P, Conrad MJ, Bohula-May E, Deenadayalu N, Braunwald E, Giugliano RP, Newby LK, Sabatine MS, Morrow DAClinical cardiologyPrognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T. Clin Cardiol. 2015 Apr; 38(4):230-5.Clin Cardiol2015-03-03T00:00:002015Prognostic implications of low level cardiac troponin elevation using high-sensitivity cardiac troponin T.25696877Sabatine MS, Mega JLHematology. American Society of Hematology. Education ProgramPharmacogenomics of antiplatelet drugs. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):343-7.Hematology Am Soc Hematol Educ Program2014-11-18T00:00:002014Pharmacogenomics of antiplatelet drugs.25773607Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EAThe New England journal of medicineEfficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015 Apr 16; 372(16):1500-9.N Engl J Med2015-03-15T00:00:002015Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.25773268Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MSThe New England journal of medicineLong-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 07; 372(19):1791-800.N Engl J Med2015-03-14T00:00:002015Long-term use of ticagrelor in patients with prior myocardial infarction.Authorship 596472Authorship 614168Authorship 2866431Authorship 3754454Authorship 3780166Authorship 3829791Authorship 4332021Authorship 4862665Authorship 467585326119654Khera AV, Qamar A, Murphy SA, Cannon CP, Sabatine MS, Rader DJThe American journal of cardiologyOn-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study). Am J Cardiol. 2015 Sep 01; 116(5):694-8.Am J Cardiol2015-06-04T00:00:002015On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).Authorship 587027Authorship 1736536Authorship 80924917Authorship 81324513Authorship 812488225769357Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MSLancet (London, England)Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 06; 385(9984):2280-7.Lancet2015-03-11T00:00:002015Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.25748612Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MSLancet (London, England)Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 06; 385(9984):2264-2271.Lancet2015-03-04T00:00:002015Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials.26088304Giugliano RP, Sabatine MSJournal of the American College of CardiologyAre PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? J Am Coll Cardiol. 2015 Jun 23; 65(24):2638-2651.J Am Coll Cardiol2015-06-23T00:00:002015Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?Authorship 284137Authorship 8145091026150476Beatty AL, Ku IA, Bibbins-Domingo K, Christenson RH, DeFilippi CR, Ganz P, Ix JH, Lloyd-Jones D, Omland T, Sabatine MS, Schiller NB, Shlipak MG, Skali H, Takeuchi M, Vittinghoff E, Whooley MAJournal of the American Heart AssociationTraditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study. J Am Heart Assoc. 2015 Jul 06; 4(7).J Am Heart Assoc2015-07-06T00:00:002015Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study.Authorship 3124921Authorship 3661624Authorship 4477863Authorship 8262015Authorship 825531126295078Sabatine MS, Wasserman SM, Stein EAThe New England journal of medicinePCSK9 Inhibitors and Cardiovascular Events. N Engl J Med. 2015 08 20; 373(8):774-5.N Engl J Med2015-08-20T00:00:002015PCSK9 Inhibitors and Cardiovascular Events.Authorship 4687043Authorship 5360181Authorship 597733Authorship 600857Authorship 612189Authorship 612264Authorship 834414725538086Bonaca MP, O'Malley RG, Murphy SA, Jarolim P, Conrad MJ, Braunwald E, Sabatine MS, Morrow DAEuropean heart journal. Acute cardiovascular carePrognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. Eur Heart J Acute Cardiovasc Care. 2015 Oct; 4(5):431-40.Eur Heart J Acute Cardiovasc Care2014-12-23T00:00:002014Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36.Authorship 8363203Authorship 836403226398078Bonaca MP, Braunwald E, Sabatine MSThe New England journal of medicineLong-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015 09 24; 373(13):1274-5.N Engl J Med2015-09-24T00:00:002015Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.25771732Desai NR, Sabatine MSTrends in cardiovascular medicinePCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc Med. 2015 Oct; 25(7):567-74.Trends Cardiovasc Med2015-02-11T00:00:002015PCSK9 inhibition in patients with hypercholesterolemia.Authorship 3642989Authorship 3980733Authorship 4423109Authorship 518645326491109Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, López-Sendón J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, Aylward P, Magnani G, Jensen EC, Held P, Braunwald E, Sabatine MSEuropean heart journalIschaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016 Apr 07; 37(14):1133-42.Eur Heart J2015-10-21T00:00:002015Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.26443023Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M, Kuder J, Im K, Aylward P, Ardissino D, Isaza D, Parkhomenko A, Goudev AR, Dellborg M, Kontny F, Corbalan R, Medina F, Jensen EC, Held P, Braunwald E, Sabatine MS, Bonaca MPEuropean heart journalEfficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016 Jan 21; 37(4):400-8.Eur Heart J2015-10-05T00:00:002015Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.Authorship 4917902Authorship 5046624Authorship 5168361Authorship 86018320Authorship 8594402Authorship 8607841226248569Montalescot G, Sabatine MSEuropean heart journalOral dual antiplatelet therapy: what have we learnt from recent trials? Eur Heart J. 2016 Jan 21; 37(4):344-52.Eur Heart J2015-08-06T00:00:002015Oral dual antiplatelet therapy: what have we learnt from recent trials?26324537Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DLEuropean heart journalLong-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016 Jan 21; 37(4):390-9.Eur Heart J2015-08-31T00:00:002015Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.Authorship 591347Authorship 600607Authorship 794933Authorship 8965210Authorship 8658331Authorship 8708991526965534Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MSJournal of the American College of CardiologyPlatelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2016 Mar 15; 67(10):1145-1154.J Am Coll Cardiol2016-03-15T00:00:002016Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.26920601Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, Wasserman SM, Scott R, Sever PS, Pedersen TRAmerican heart journalRationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016 Mar; 173:94-101.Am Heart J2015-12-17T00:00:002015Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial.Authorship 608940Authorship 833676Authorship 872078126974988Sabatine MSCleveland Clinic journal of medicineAdvances in the treatment of dyslipidemia. Cleve Clin J Med. 2016 Mar; 83(3):181-6.Cleve Clin J Med2016-03-01T00:00:002016Advances in the treatment of dyslipidemia.Authorship 8734911826573179Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet JP, Delaney JT, Hulot JS, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MSJournal of thrombosis and thrombolysisPON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. J Thromb Thrombolysis. 2016 Apr; 41(3):374-83.J Thromb Thrombolysis2016-04-01T00:00:002016PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.Authorship 3572846Authorship 1817232Authorship 87468921Authorship 8778552827043082O'Donoghue ML, Glaser R, Cavender MA, Aylward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KA, Gutierrez JA, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay JF, Ruda M, Steg PG, Theroux P, Wiviott SD, Laws I, Sabatine MS, Morrow DAJAMAEffect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA. 2016 Apr 19; 315(15):1591-9.JAMA2016-04-19T00:00:002016Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.Authorship 4399641Authorship 5032044Authorship 881913527179740Xu H, Li W, Yang J, Wiviott SD, Sabatine MS, Peterson ED, Xian Y, Roe MT, Zhao W, Wang Y, Tang X, Jia X, Wu Y, Gao R, Yang YAmerican heart journalThe China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. Am Heart J. 2016 May; 175:193-201.e3.Am Heart J2015-04-17T00:00:002015The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China.Authorship 883423927207959O'Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW, Murphy SA, Gerszten RE, Sabatine MSJournal of the American Heart AssociationMultimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016 05 20; 5(5).J Am Heart Assoc2016-05-20T00:00:002016Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.Authorship 884737327102113Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M, Somaratne R, Wasserman SM, Scott R, Stein EAJournal of lipid researchPCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res. 2016 06; 57(6):1086-96.J Lipid Res2016-04-21T00:00:002016PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.Authorship 88564511Authorship 8859572027046162Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MTB, Jensen EC, Held P, Braunwald E, Sabatine MSJournal of the American College of CardiologyTicagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2016 Jun 14; 67(23):2719-2728.J Am Coll Cardiol2016-04-01T00:00:002016Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.27046160Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, Sabatine MS, Steg PGJournal of the American College of CardiologyReduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016 Jun 14; 67(23):2732-2740.J Am Coll Cardiol2016-04-01T00:00:002016Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.Authorship 618713Authorship 627659Authorship 5642911Authorship 888542127327798Sabatine MSJAMAUsing Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction. JAMA. 2016 Jun 21; 315(23):2525-6.JAMA2016-06-21T00:00:002016Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.2Assistant Professor1Associate Professor0Full Professor4Instructor3LecturerAuthorship 601991Authorship 613797Authorship 9627715Authorship 89103911Authorship 890585927417011Bonaca MP, O'Malley RG, Jarolim P, Scirica BM, Murphy SA, Conrad MJ, Cannon CP, White HD, Braunwald E, Morrow DA, Sabatine MSJournal of the American College of CardiologySerial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.J Am Coll Cardiol2016-07-19T00:00:002016Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease.27009617Carreras ET, Hochholzer W, Frelinger AL, Nordio F, O'Donoghue ML, Wiviott SD, Angiolillo DJ, Michelson AD, Sabatine MS, Mega JLThrombosis and haemostasisDiabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77.Thromb Haemost2016-03-24T00:00:002016Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.Authorship 582382Authorship 89328922Authorship 8931172Authorship 893378127438098Benson MD, Sabatine MS, Gerszten REJAMA cardiologyThe Prospects for Cardiovascular Proteomics: A Glass Approaching Half Full. JAMA Cardiol. 2016 06 01; 1(3):245-6.JAMA Cardiol2016-06-01T00:00:002016The Prospects for Cardiovascular Proteomics: A Glass Approaching Half Full.27438319Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Špinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MSJAMA cardiologyLong-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016 Jul 01; 1(4):425-32.JAMA Cardiol2016-07-01T00:00:002016Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.27437651Sabatine MSJAMA cardiologyNurturing Nature-Exploring the Possible Role of Epigenetics in Dyslipidemia. JAMA Cardiol. 2016 04 01; 1(1):36.JAMA Cardiol2016-04-01T00:00:002016Nurturing Nature-Exploring the Possible Role of Epigenetics in Dyslipidemia.Authorship 601071Authorship 615627Authorship 89462213Authorship 8947151Authorship 8946371127444932Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, Benson MD, O'Sullivan JF, Keshishian H, Farrell LA, Fifer MA, Vasan RS, Sabatine MS, Larson MG, Carr SA, Wang TJ, Gerszten RECirculationAptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation. 2016 Jul 26; 134(4):270-85.Circulation2016-07-26T00:00:002016Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.27440003Bohula EA, Bonaca MP, Braunwald E, Aylward PE, Corbalan R, De Ferrari GM, He P, Lewis BS, Merlini PA, Murphy SA, Sabatine MS, Scirica BM, Morrow DACirculationAtherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation. 2016 Jul 26; 134(4):304-13.Circulation2016-07-26T00:00:002016Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.27422124Sabatine MS, Underberg JA, Koren M, Baum SJPostgraduate medicineFocus on PCSK9 Inhibitors: From Genetics to Clinical Practice. Postgrad Med. 2016 Oct; 128 Suppl 1:31-9.Postgrad Med2016-07-14T00:00:002016Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice.Authorship 4934923Authorship 535107Authorship 799422Authorship 901845327532444Magnani G, Bonaca MP, Sabatine MSEuropean heart journal. Cardiovascular pharmacotherapyEditorial on PEGASUS-TIMI 54. Eur Heart J Cardiovasc Pharmacother. 2015 Oct; 1(4):217-9.Eur Heart J Cardiovasc Pharmacother2015-06-23T00:00:002015Editorial on PEGASUS-TIMI 54.Authorship 5135092Authorship 9095911527036918Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SCJournal of the American College of Cardiology2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016 09 06; 68(10):1082-115.J Am Coll Cardiol2016-03-29T00:00:0020162016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Authorship 5339377Authorship 5460878Authorship 55936712019-07-31DAS, SAUMYA2013-08-01Plasma miRNA predictors of adverse mechanical and electrical remodeling after MIUH3TR0009012012-08-31SABATINE, MARC S2009-09-30Genetic Risk Stratification to Identify Individuals for Early Statin TherapyRC1HL0996342011-08-31SABATINE, MARC S2009-09-30Biomarkers of Prognosis and Response to Therapy in Acute Coronary SyndromesRC1HL0996922015-07-31DAS, SAUMYA2013-08-01Plasma miRNA predictors of adverse mechanical and electrical remodeling after MIUH2TR0009012016-01-31GERSZTEN, ROBERT E2010-03-15Metabolomic Biomarkers of Early Myocardial InjuryR01HL0982801900-01-01SABATINE, MARC S2001-07-19Development of Novel Protein Markers of IschemiaF32HL0684552014-06-30GERSZTEN, ROBERT E2009-08-01Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial InjuryR01HL0967382013-12-31SABATINE, MARC S2009-01-01Novel Biomarkers to Identify Vulnerable Patients with Coronary Artery DiseaseR01HL0943902007-07-31SABATINE, MARC S2002-09-30Genetic Predictors of Outcome in Acute MIR01HL0728792014-05-31SABATINE, MARC S2009-08-15Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein BiomarkersR01HL098082Co-Principal InvestigatorCo-Principal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 617651Authorship 622452Authorship 623125Authorship 9118671527026020Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SCCirculation2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 06; 134(10):e123-55.Circulation2016-03-29T00:00:0020162016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.Authorship 9156632427518659Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, Roe MT, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, Gibson MThe New England journal of medicineSharing Data from Cardiovascular Clinical Trials--A Proposal. N Engl J Med. 2016 Aug 04; 375(5):407-9.N Engl J Med2016-08-04T00:00:002016Sharing Data from Cardiovascular Clinical Trials--A Proposal.Authorship 91679719Authorship 916864227548077Bonaca MP, Sabatine MSJAMA cardiologyAntiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction. JAMA Cardiol. 2016 09 01; 1(6):627-8.JAMA Cardiol2016-09-01T00:00:002016Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction.27576775Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Špinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MSCirculationPrevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016 Sep 20; 134(12):861-71.Circulation2016-08-30T00:00:002016Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).Authorship 917773827673306Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MSJAMAAssociation Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27; 316(12):1289-97.JAMA2016-09-27T00:00:002016Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.Authorship 738117Authorship 987397Authorship 4086021Authorship 9203561527751237Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O'Gara PT, Sabatine MS, Smith PK, Smith SC, Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis JS, Joglar JA, Pressler SJ, Wijeysundera DNThe Journal of thoracic and cardiovascular surgery2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2016 11; 152(5):1243-1275.J Thorac Cardiovasc Surg2016-11-01T00:00:0020162016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Authorship 4306851Authorship 597734Authorship 598866Authorship 8294814Authorship 1971051Authorship 2565725Authorship 3024511Authorship 3112175Authorship 3166777Authorship 9406791127959767Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MSThe New England journal of medicineVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016 12 01; 375(22):2144-2153.N Engl J Med2016-12-01T00:00:002016Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.Authorship 43217613Authorship 4480822Authorship 5461232Authorship 9528911Authorship 952808328110294Sabatine MSEuropean heart journalProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J. 2017 Aug 01; 38(29):2256-2258.Eur Heart J2017-08-01T00:00:002017Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic.28118447Silverman MG, Im K, Sabatine MSJAMAInterventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply. JAMA. 2017 01 24; 317(4):440.JAMA2017-01-24T00:00:002017Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.Authorship 606934Authorship 629039Authorship 680712Authorship 95939210974186Sabatine MS, Jang IKThe American journal of medicineThe use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med. 2000 Aug 15; 109(3):224-37.Am J Med2000-08-15T00:00:002000The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.11577259Januzzi JL, Chae CU, Sabatine MS, Jang IKJournal of thrombosis and thrombolysisElevation in serum troponin I predicts the benefit of tirofiban. J Thromb Thrombolysis. 2001 May; 11(3):211-5.J Thromb Thrombolysis2001-05-01T00:00:002001Elevation in serum troponin I predicts the benefit of tirofiban.15165915Giugliano RP, Sabatine MS, Gibson CM, Roe MT, Harrington RA, Murphy SA, Morrow DA, Antman EM, Braunwald EThe American journal of cardiologyCombined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.Am J Cardiol2004-06-01T00:00:002004Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion.15894966Mega JL, Morrow DA, Sabatine MS, Zhao XQ, Snapinn SM, DiBattiste PM, Gibson CM, Antman EM, Braunwald E, Théroux PAmerican heart journalCorrelation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Am Heart J. 2005 May; 149(5):846-50.Am Heart J2005-05-01T00:00:002005Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.11948889Sheynberg BV, Jang IK, Han RO, Sabatine MS, Brown DF, Dinsmore RCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & InterventionsComparison of two different methods of quantitative coronary angiography in patients with acute coronary syndromes. Catheter Cardiovasc Interv. 2002 Apr; 55(4):442-9.Catheter Cardiovasc Interv2002-04-01T00:00:002002Comparison of two different methods of quantitative coronary angiography in patients with acute coronary syndromes.12422146Cooper HA, de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Gibson CM, Antman EM, Braunwald EAmerican heart journalMinimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration. Am Heart J. 2002 Nov; 144(5):790-5.Am Heart J2002-11-01T00:00:002002Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration.15374786Morrow DA, Sabatine MS, Antman EM, Cannon CP, Braunwald E, Theroux PThe American journal of cardiologyUsefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Am J Cardiol. 2004 Sep 15; 94(6):774-6.Am J Cardiol2004-09-15T00:00:002004Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).Authorship 966508728122070Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MSJAMA cardiologyAssociation Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. JAMA Cardiol. 2017 05 01; 2(5):556-560.JAMA Cardiol2017-05-01T00:00:002017Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.Authorship 969422928207168Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Wasserman SM, Ott BRClinical cardiologyDesign and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 2017 Feb; 40(2):59-65.Clin Cardiol2017-02-16T00:00:002017Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.75 Francis StBrigham and Women's HospitalCardiology75 Francis StBoston02115MAAuthorship 9705292Authorship 9717101Authorship 9708101428304224Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TRThe New England journal of medicineEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 05 04; 376(18):1713-1722.N Engl J Med2017-03-17T00:00:002017Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.28291870Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJJAMA cardiologyLong-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.JAMA Cardiol2017-06-01T00:00:002017Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.28300867Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RFThrombosis and haemostasisConsistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thromb Haemost. 2017 05 03; 117(5):940-947.Thromb Haemost2017-03-16T00:00:002017Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.17624497Pride YB, Buros JL, Lord E, Southard MC, Harrigan CJ, Ciaglo LN, Sabatine MS, Cannon CP, Gibson CMJournal of thrombosis and thrombolysisAngiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days. J Thromb Thrombolysis. 2008 Oct; 26(2):106-12.J Thromb Thrombolysis2007-07-12T00:00:002007Angiographic perfusion score in patients treated with PCI at late angiography following fibrinolytic administration for ST-segment elevation myocardial infarction is associated with morbidity and mortality at 30 days.20102867Harkness JR, Sabatine MS, Braunwald E, Morrow DA, Sloan S, Wiviott SD, Giugliano RP, Antman EM, Cannon CP, Scirica BMAmerican heart journalExtent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.Am Heart J2010-01-01T00:00:002010Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction.Authorship 9732991528335837Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S, James SK, Wallentin L, Clemmensen P, Roe MT, Ohman EM, Harrington RA, Mega JL, Bhatt DL, Sabatine MS, O'Donoghue MLJournal of the American College of CardiologyPotent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559.J Am Coll Cardiol2017-03-28T00:00:002017Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials.15758000Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald EThe New England journal of medicineAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179-89.N Engl J Med2005-03-09T00:00:002005Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.Authorship 974054228355422Turakhia MP, Sabatine MSJAMA cardiologyHow We Evaluate Biomarker Studies. JAMA Cardiol. 2017 05 01; 2(5):524.JAMA Cardiol2017-05-01T00:00:002017How We Evaluate Biomarker Studies.16880323O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MSCirculationPrognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 08; 114(6):550-7.Circulation2006-07-31T00:00:002006Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.16750703Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald EJournal of the American College of CardiologyIntensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.J Am Coll Cardiol2006-05-04T00:00:002006Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.17717132Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Rifai N, McCabe CH, Braunwald EClinical chemistryClinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.Clin Chem2007-08-23T00:00:002007Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.12446059Sabatine MS, Morrow DA, Cannon CP, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Braunwald E, Gibson CMJournal of the American College of CardiologyRelationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol. 2002 Nov 20; 40(10):1761-8.J Am Coll Cardiol2002-11-20T00:00:002002Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.12706919Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald EJournal of the American College of CardiologyEvaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003 Apr 16; 41(8):1264-72.J Am Coll Cardiol2003-04-16T00:00:002003Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.12127617Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald EThe American journal of cardiologyValidation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.Am J Cardiol2002-08-01T00:00:002002Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry.11564399Januzzi JL, Sabatine MS, Choi JC, Abernethy WB, Isselbacher EMThe American journal of cardiologyRefractory systemic hypertension following type B aortic dissection. Am J Cardiol. 2001 Sep 15; 88(6):686-8.Am J Cardiol2001-09-15T00:00:002001Refractory systemic hypertension following type B aortic dissection.21658559Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, Keeley EC, Cigarroa JE, Lange RA, Hillis LD, de Lemos JAJournal of the American College of CardiologyMyocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol. 2011 Jun 14; 57(24):2398-405.J Am Coll Cardiol2011-06-14T00:00:002011Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study.Morrow DA, Sabatine MS, Cannon CP, Murphy SA, Brennan ML, Hazen SL, Braunwald E.J Am Coll Cardiol.Concurrent evaluation of novel cardiac biomarkers in ACS: myeloperoxidase, sCD40L, C-reactive protein and risk of death or recurrent ischemia in TACTICS-TIMI 18. J Am Coll Cardiol. 2006; 47(Suppl A):196A.2006-01-01T00:00:002006Concurrent evaluation of novel cardiac biomarkers in ACS: myeloperoxidase, sCD40L, C-reactive protein and risk of death or recurrent ischemia in TACTICS-TIMI 1812106926de Lemos JA, Morrow DA, Gibson CM, Murphy SA, Sabatine MS, Rifai N, McCabe CH, Antman EM, Cannon CP, Braunwald EJournal of the American College of CardiologyThe prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J Am Coll Cardiol. 2002 Jul 17; 40(2):238-44.J Am Coll Cardiol2002-07-17T00:00:002002The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies.12745096Wong GC, Frisch D, Murphy SA, Sabatine MS, Pai R, James D, Kraimer N, Katsiyiannis PT, Marble SJ, DiBattiste PM, Demopoulos LA, Gourlay SG, Barron HV, Cannon CP, Gibson CMThe American journal of cardiologyTime for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction. Am J Cardiol. 2003 May 15; 91(10):1163-7.Am J Cardiol2003-05-15T00:00:002003Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction.12578870de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald ECirculationAssociation between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003 Feb 11; 107(5):690-5.Circulation2003-02-11T00:00:002003Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.17160548Verheugt FW, Montalescot G, Sabatine MS, Soulat L, Lambert Y, Lapostolle F, Adgey J, Cannon CPJournal of thrombosis and thrombolysisPrehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial. J Thromb Thrombolysis. 2007 Jun; 23(3):173-9.J Thromb Thrombolysis2006-12-09T00:00:002006Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial.20569707Sherwood MW, Morrow DA, Scirica BM, Jiang S, Bode C, Rifai N, Gerszten RE, Gibson CM, Cannon CP, Braunwald E, Sabatine MSAmerican heart journalEarly dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1.Am Heart J2010-06-01T00:00:002010Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28.21641362Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, Rifai N, Cannon CP, Morrow DAAmerican heart journalAssessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun; 161(6):1147-55.e1.Am Heart J2011-05-11T00:00:002011Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22).15967973Sabatine MSCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienneWhen prognosis precedes diagnosis: putting the cart before the horse. CMAJ. 2005 Jun 21; 172(13):1697-8.CMAJ2005-06-21T00:00:002005When prognosis precedes diagnosis: putting the cart before the horse.15846259Sabatine MS, McCabe CH, Gibson CM, Cannon CPAmerican heart journalDesign and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial. Am Heart J. 2005 Feb; 149(2):227-33.Am Heart J2005-02-01T00:00:002005Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trial.16271628Sabatine MSLancet (London, England)Something old, something new: beta blockers and clopidogrel in acute myocardial infarction. Lancet. 2005 Nov 05; 366(9497):1587-9.Lancet2005-11-05T00:00:002005Something old, something new: beta blockers and clopidogrel in acute myocardial infarction.16375623Baggish AL, Sabatine MSExpert review of cardiovascular therapyClopidogrel use in coronary artery disease. Expert Rev Cardiovasc Ther. 2006 Jan; 4(1):7-15.Expert Rev Cardiovasc Ther2006-01-01T00:00:002006Clopidogrel use in coronary artery disease.9448155Sabatine MS, Laufer T, Glimcher LH, Widmer M, Winn H, Auchincloss HTransplantationDelayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts. Transplantation. 1998 Jan 15; 65(1):113-20.Transplantation1998-01-15T00:00:001998Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts.12881457Morrow DA, Rifai N, Sabatine MS, Ayanian S, Murphy SA, de Lemos JA, Braunwald E, Cannon CPClinical chemistryEvaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem. 2003 Aug; 49(8):1396-8.Clin Chem2003-08-01T00:00:002003Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes.15261928Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, Gibson CM, Antman EM, Braunwald EJournal of the American College of CardiologyB-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004 Jul 21; 44(2):335-9.J Am Coll Cardiol2004-07-21T00:00:002004B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.15642555Kashani A, Gibson CM, Murphy SA, Sabatine MS, Morrow DA, Antman EM, Giugliano RPThe American journal of cardiologyAngiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):228-33.Am J Cardiol2005-01-15T00:00:002005Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.16950180Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CPThe American journal of cardiologyUsefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15; 98(6):761-3.Am J Cardiol2006-08-02T00:00:002006Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28).17600039Scirica BM, Morrow DA, Sadowski Z, Ruda M, Nicolau JC, Giugliano RP, Wiviott SD, Sabatine MS, Shui A, Antman EM, Braunwald EEuropean heart journalA strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study. Eur Heart J. 2007 Sep; 28(17):2070-6.Eur Heart J2007-06-28T00:00:002007A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.9404775Sabatine MS, Oelberg DA, Mark EJ, Kanarek DChestPulmonary cholesterol crystal embolization. Chest. 1997 Dec; 112(6):1687-92.Chest1997-12-01T00:00:001997Pulmonary cholesterol crystal embolization.18237683Gibson CM, Pride YB, Buros JL, Lord E, Shui A, Murphy SA, Pinto DS, Zimetbaum PJ, Sabatine MS, Cannon CP, Josephson MEJournal of the American College of CardiologyAssociation of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 05; 51(5):546-51.J Am Coll Cardiol2008-02-05T00:00:002008Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction.11586953de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald EThe New England journal of medicineThe prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 04; 345(14):1014-21.N Engl J Med2001-10-04T00:00:002001The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.11956114Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald ECirculationMultimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002 Apr 16; 105(15):1760-3.Circulation2002-04-16T00:00:002002Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.12651803Morrow DA, de Lemos JA, Sabatine MS, Antman EMClinical chemistryThe search for a biomarker of cardiac ischemia. Clin Chem. 2003 Apr; 49(4):537-9.Clin Chem2003-04-01T00:00:002003The search for a biomarker of cardiac ischemia.22714699Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MSClinical cardiologyDesign and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012; 35(7):385-91.Clin Cardiol2012-06-19T00:00:002012Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.19414633Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MSCirculationCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009 May 19; 119(19):2553-60.Circulation2009-05-04T00:00:002009Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.23414791Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltyte Benth J, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS, Braunwald EJournal of the American College of CardiologyPrognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol. 2013 Mar 26; 61(12):1240-9.J Am Coll Cardiol2013-02-13T00:00:002013Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.21084706Williams MS, Weiss EJ, Sabatine MS, Simon DI, Bahou WF, Becker LC, Parise LV, Dauerman HL, French PA, Smyth SS, Becker RCArteriosclerosis, thrombosis, and vascular biologyGenetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol. 2010 Dec; 30(12):2372-84.Arterioscler Thromb Vasc Biol2010-12-01T00:00:002010Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development.Sabatine MS, Ray KK, Campos H, Iakoubova OA, Kirchgessner TG, Ranade K, Tsuchihashi Z, Ploughman LM, Zerba KE, Devlin JJ, Shaw PM, Sacks FM, Braunwald E.J Am Coll CardiolPolymorphisms in lipoprotein and lipid metabolism genes predict response to pravastatin therapy. J Am Coll Cardiol. 2005; 45(Suppl A):3A.2005-03-01T00:00:002005Polymorphisms in lipoprotein and lipid metabolism genes predict response to pravastatin therapyScirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E.CirculationCorrelates and outcomes associated with ST segment resolution after fibrinolytic therapy - Results from the ECG CLARITY-TIMI 28 substudy. Circulation. 2005; 112(Suppl II):II-486.2005-11-03T00:00:002005Correlates and outcomes associated with ST segment resolution after fibrinolytic therapy - Results from the ECG CLARITY-TIMI 28 substudyAuthorship 997855528674100Watts GF, Chan DC, Somaratne R, Wasserman SM, Sabatine MSCirculationResponse by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation. 2017 07 04; 136(1):120-121.Circulation2017-07-04T00:00:002017Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism".17548728Ray KK, Morrow DA, Sabatine MS, Shui A, Rifai N, Cannon CP, Braunwald ECirculationLong-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation. 2007 Jun 19; 115(24):3071-8.Circulation2007-06-04T00:00:002007Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.18339606Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, Rifai N, Cannon CP, Hazen SLEuropean heart journalConcurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008 May; 29(9):1096-102.Eur Heart J2008-03-12T00:00:002008Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18.18440341Sabatine MS, Hamdalla HN, Mehta SR, Fox KA, Topol EJ, Steinhubl SR, Cannon CPAmerican heart journalEfficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. Am Heart J. 2008 May; 155(5):910-7.Am Heart J2008-02-21T00:00:002008Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.16847010Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CMEuropean heart journalAngiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J. 2006 Sep; 27(17):2040-5.Eur Heart J2006-07-17T00:00:002006Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.18222353Iakoubova OA, Tong CH, Rowland CM, Kirchgessner TG, Young BA, Arellano AR, Shiffman D, Sabatine MS, Campos H, Packard CJ, Pfeffer MA, White TJ, Braunwald E, Shepherd J, Devlin JJ, Sacks FMJournal of the American College of CardiologyAssociation of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol. 2008 Jan 29; 51(4):435-43.J Am Coll Cardiol2008-01-29T00:00:002008Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.18312757Hsia J, Jablonski KA, Rice MM, Sabatine MS, Zabalgoitia M, Maggioni A, Cuddy TE, Domanski MJ, Geller NL, Flaker G, Solomon S, Omland T, Rouleau JLThe American journal of cardiologySudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol. 2008 Feb 15; 101(4):457-61.Am J Cardiol2008-02-15T00:00:002008Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function.19015285Matheny ME, Morrow DA, Ohno-Machado L, Cannon CP, Sabatine MS, Resnic FSMedical decision making : an international journal of the Society for Medical Decision MakingValidation of an automated safety surveillance system with prospective, randomized trial data. Med Decis Making. 2009 Mar-Apr; 29(2):247-56.Med Decis Making2008-11-17T00:00:002008Validation of an automated safety surveillance system with prospective, randomized trial data.21194676Lanktree MB, Guo Y, Murtaza M, Glessner JT, Bailey SD, Onland-Moret NC, Lettre G, Ongen H, Rajagopalan R, Johnson T, Shen H, Nelson CP, Klopp N, Baumert J, Padmanabhan S, Pankratz N, Pankow JS, Shah S, Taylor K, Barnard J, Peters BJ, Maloney CM, Lobmeyer MT, Stanton A, Zafarmand MH, Romaine SP, Mehta A, van Iperen EP, Gong Y, Price TS, Smith EN, Kim CE, Li YR, Asselbergs FW, Atwood LD, Bailey KM, Bhatt D, Bauer F, Behr ER, Bhangale T, Boer JM, Boehm BO, Bradfield JP, Brown M, Braund PS, Burton PR, Carty C, Chandrupatla HR, Chen W, Connell J, Dalgeorgou C, Boer Ad, Drenos F, Elbers CC, Fang JC, Fox CS, Frackelton EC, Fuchs B, Furlong CE, Gibson Q, Gieger C, Goel A, Grobbee DE, Hastie C, Howard PJ, Huang GH, Johnson WC, Li Q, Kleber ME, Klein BE, Klein R, Kooperberg C, Ky B, Lacroix A, Lanken P, Lathrop M, Li M, Marshall V, Melander O, Mentch FD, Meyer NJ, Monda KL, Montpetit A, Murugesan G, Nakayama K, Nondahl D, Onipinla A, Rafelt S, Newhouse SJ, Otieno FG, Patel SR, Putt ME, Rodriguez S, Safa RN, Sawyer DB, Schreiner PJ, Simpson C, Sivapalaratnam S, Srinivasan SR, Suver C, Swergold G, Sweitzer NK, Thomas KA, Thorand B, Timpson NJ, Tischfield S, Tobin M, Tomaszewski M, Tomaszweski M, Verschuren WM, Wallace C, Winkelmann B, Zhang H, Zheng D, Zhang L, Zmuda JM, Clarke R, Balmforth AJ, Danesh J, Day IN, Schork NJ, de Bakker PI, Delles C, Duggan D, Hingorani AD, Hirschhorn JN, Hofker MH, Humphries SE, Kivimaki M, Lawlor DA, Kottke-Marchant K, Mega JL, Mitchell BD, Morrow DA, Palmen J, Redline S, Shields DC, Shuldiner AR, Sleiman PM, Smith GD, Farrall M, Jamshidi Y, Christiani DC, Casas JP, Hall AS, Doevendans PA, Christie JD, Berenson GS, Murray SS, Illig T, Dorn GW, Cappola TP, Boerwinkle E, Sever P, Rader DJ, Reilly MP, Caulfield M, Talmud PJ, Topol E, Engert JC, Wang K, Dominiczak A, Hamsten A, Curtis SP, Silverstein RL, Lange LA, Sabatine MS, Trip M, Saleheen D, Peden JF, Cruickshanks KJ, März W, O'Connell JR, Klungel OH, Wijmenga C, Maitland-van der Zee AH, Schadt EE, Johnson JA, Jarvik GP, Papanicolaou GJ, Grant SF, Munroe PB, North KE, Samani NJ, Koenig W, Gaunt TR, Anand SS, van der Schouw YT, Soranzo N, Fitzgerald GA, Reiner A, Hegele RA, Hakonarson H, Keating BJAmerican journal of human geneticsMeta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet. 2011 Jan 07; 88(1):6-18.Am J Hum Genet2010-12-30T00:00:002010Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height.22088980Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MSJAMADosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8.JAMA2011-11-16T00:00:002011Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.20447535Bonaca M, Scirica B, Sabatine M, Dalby A, Spinar J, Murphy SA, Jarolim P, Braunwald E, Morrow DAJournal of the American College of CardiologyProspective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010 May 11; 55(19):2118-24.J Am Coll Cardiol2010-05-11T00:00:002010Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I.21693744Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KKJAMARisk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011 Jun 22; 305(24):2556-64.JAMA2011-06-22T00:00:002011Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.22974808Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, Waxman S, Domanski MJ, Srinivas PR, Narula JJACC. Cardiovascular imagingDetection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions. JACC Cardiovasc Imaging. 2012 Sep; 5(9):941-55.JACC Cardiovasc Imaging2012-09-01T00:00:002012Detection of high-risk atherosclerotic plaque: report of the NHLBI Working Group on current status and future directions.Sabatine MS, Antman EM, Ganz LI, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Diagnosis of cardiac arrhythmias. Lilly LS, ed. Pathophysiology of Heart Disease. 1998; 249-66.1998-01-04T00:00:001998Diagnosis of cardiac arrhythmiasAuthorship 100178815Authorship 10069712Authorship 100603212Authorship 10019141Authorship 100753311Authorship 100750619Authorship 10072031128834471Sabatine MS, Giugliano RP, Pedersen TRThe New England journal of medicineEvolocumab in Patients with Cardiovascular Disease. N Engl J Med. 2017 08 24; 377(8):787-8.N Engl J Med2017-08-24T00:00:002017Evolocumab in Patients with Cardiovascular Disease.28750695Magnuson EA, Li H, Wang K, Vilain K, Shafiq A, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS, Cohen DJJournal of the American College of CardiologyCost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. J Am Coll Cardiol. 2017 Aug 01; 70(5):527-538.J Am Coll Cardiol2017-08-01T00:00:002017Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.28832867Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MSJAMA cardiologyCost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 10 01; 2(10):1069-1078.JAMA Cardiol2017-10-01T00:00:002017Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.28859947Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MSLancet (London, England)Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28; 390(10106):1962-1971.Lancet2017-08-28T00:00:002017Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.28846118Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MSJAMAAssociation of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017 09 12; 318(10):947-956.JAMA2017-09-12T00:00:002017Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.28813214Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BRThe New England journal of medicineCognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 08 17; 377(7):633-643.N Engl J Med2017-08-17T00:00:002017Cognitive Function in a Randomized Trial of Evolocumab.28813546Koren MJ, Sabatine MSJAMA cardiologyPCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply. JAMA Cardiol. 2017 10 01; 2(10):1169.JAMA Cardiol2017-10-01T00:00:002017PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply.19667110Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MSArteriosclerosis, thrombosis, and vascular biologyIdentification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol. 2009 Sep; 29(9):1310-5.Arterioscler Thromb Vasc Biol2009-08-10T00:00:002009Identification of genetic variants associated with response to statin therapy.19909874Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PBJournal of the American College of CardiologyThe relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009 Nov 17; 54(21):1935-45.J Am Coll Cardiol2009-11-17T00:00:002009The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.20298924Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald EJournal of the American College of CardiologyB-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010 Mar 23; 55(12):1189-1196.J Am Coll Cardiol2010-03-23T00:00:002010B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial.20801494Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MSLancet (London, England)Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010 Oct 16; 376(9749):1312-9.Lancet2010-10-16T00:00:002010Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.20966402Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KCArteriosclerosis, thrombosis, and vascular biologyGrowth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):203-10.Arterioscler Thromb Vasc Biol2010-10-21T00:00:002010Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.20978260Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MSJAMAReduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27; 304(16):1821-30.JAMA2010-10-27T00:00:002010Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Authorship 10116661028893843Deharo P, Ducrocq G, Bode C, Cohen M, Cuisset T, Mehta SR, Pollack C, Wiviott SD, Elbez Y, Sabatine MS, Steg PGCirculationTiming of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban). Circulation. 2017 Nov 14; 136(20):1895-1907.Circulation2017-09-11T00:00:002017Timing of Angiography and Outcomes in High-Risk Patients With Non-ST-Segment-Elevation Myocardial Infarction Managed Invasively: Insights From the TAO Trial (Treatment of Acute Coronary Syndrome With Otamixaban).11956134Sabatine MS, Aretz HT, Fang LS, Dec GWCirculationImages in cardiovascular medicine. Fibrillary/immunotactoid glomerulopathy with cardiac involvement. Circulation. 2002 Apr 16; 105(15):e120-1.Circulation2002-04-16T00:00:002002Images in cardiovascular medicine. Fibrillary/immunotactoid glomerulopathy with cardiac involvement.15542281Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH, Braunwald EJournal of the American College of CardiologyAcute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004 Nov 16; 44(10):1988-95.J Am Coll Cardiol2004-11-16T00:00:002004Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.16476853Armstrong EJ, Morrow DA, Sabatine MSCirculationInflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation. 2006 Feb 14; 113(6):e72-5.Circulation2006-02-14T00:00:002006Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines.16801465Solomon SD, Rice MM, A Jablonski K, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald ECirculationRenal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006 Jul 04; 114(1):26-31.Circulation2006-06-26T00:00:002006Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.Authorship 101264620Authorship 10125171Authorship 1012497128927706Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TRThe lancet. Diabetes & endocrinologyCardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.Lancet Diabetes Endocrinol2017-09-15T00:00:002017Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.28882235Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MSJournal of the American College of CardiologyEfficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12; 70(11):1368-1375.J Am Coll Cardiol2017-09-12T00:00:002017Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.28768310Sabatine MS, Giugliano RPJAMA cardiologyLow-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. JAMA Cardiol. 2017 09 01; 2(9):935-936.JAMA Cardiol2017-09-01T00:00:002017Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.20403483Shiffman D, Sabatine MS, Louie JZ, Kirchgessner TG, Iakoubova OA, Campos H, Devlin JJ, Sacks FMThe American journal of cardiologyEffect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol. 2010 May 01; 105(9):1300-5.Am J Cardiol2010-03-20T00:00:002010Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial.21685905Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SANature biotechnologyA pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol. 2011 Jun 19; 29(7):635-43.Nat Biotechnol2011-06-19T00:00:002011A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.Donahoe SM, Sabatine SMExpert Rev Pharmacoeconomics Outcomes ResAddling clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Rev Pharmacoeconomics Outcomes Res. 2005; 5:751-61.2005-01-01T00:00:002005Addling clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapyScirica B, Murphy S, Wiviott S, Morrow D, Sabatine M, Gibson CM, Cannon C.J Am Coll CardiolChest pain at presentation and delayed resolution of pain in patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcome. J Am Coll Cardiol. 2005; 45(Suppl A):199A.2005-03-02T00:00:002005Chest pain at presentation and delayed resolution of pain in patients admitted with non-ST segment elevation acute coronary syndromes predicts short-term outcomeSabatine MS, Antman EMTIMI Risk Score for Unstable Angina/Non-ST-elevation Myocardial Infarction.TIMI Risk Score for Unstable Angina/Non-ST-elevation Myocardial Infarction. 2001.2001-01-01T00:00:002001TIMI Risk Score for Unstable Angina/Non-ST-elevation Myocardial InfarctionSabatine MS, editor.Pocket MedicinePocket Medicine. 2000.2000-01-01T00:00:002000Pocket Medicine11867057Januzzi JL, Sabatine MS, Eagle KA, Evangelista A, Bruckman D, Fattori R, Oh JK, Moore AG, Sechtem U, Llovet A, Gilon D, Pape L, O'Gara PT, Mehta R, Cooper JV, Hagan PG, Armstrong WF, Deeb GM, Suzuki T, Nienaber CA, Isselbacher EMThe American journal of cardiologyIatrogenic aortic dissection. Am J Cardiol. 2002 Mar 01; 89(5):623-6.Am J Cardiol2002-03-01T00:00:002002Iatrogenic aortic dissection.16401379O'Donoghue M, Sabatine MSCurrent treatment options in cardiovascular medicineAppropriate invasive and conservative treatment approaches for patients with ST-elevation MI. Curr Treat Options Cardiovasc Med. 2006 Feb; 8(1):3-11.Curr Treat Options Cardiovasc Med2006-02-01T00:00:002006Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI.Authorship 10193631329050564Thorolfsdottir RB, Sveinbjornsson G, Sulem P, Helgadottir A, Gretarsdottir S, Benonisdottir S, Magnusdottir A, Davidsson OB, Rajamani S, Roden DM, Darbar D, Pedersen TR, Sabatine MS, Jonsdottir I, Arnar DO, Thorsteinsdottir U, Gudbjartsson DF, Holm H, Stefansson KJournal of the American College of CardiologyA Missense Variant in PLEC Increases Risk of Atrial Fibrillation. J Am Coll Cardiol. 2017 Oct 24; 70(17):2157-2168.J Am Coll Cardiol2017-10-24T00:00:002017A Missense Variant in PLEC Increases Risk of Atrial Fibrillation.16239632Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, Hui L, Tsuchihashi Z, Sacks FM, Sabatine MS, Braunwald E, White TJ, Shaw PM, Dracopoli NCStrokeEvaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke. 2005 Nov; 36(11):2346-50.Stroke2005-10-20T00:00:002005Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke.17261395Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DAThe American journal of cardiologyHemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol. 2007 Feb 01; 99(3):344-8.Am J Cardiol2006-11-30T00:00:002006Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial).17323134McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CPJournal of thrombosis and thrombolysisBenefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28. J Thromb Thrombolysis. 2007 Oct; 24(2):85-91.J Thromb Thrombolysis2007-02-24T00:00:002007Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.19074516Scirica BM, Cannon CP, Sabatine MS, Jarolim P, Sloane S, Rifai N, Braunwald E, Morrow DAClinical chemistryConcentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.Clin Chem2008-12-12T00:00:002008Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.19807617Donahoe SM, Sabatine MSExpert review of pharmacoeconomics & outcomes researchAdding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy. Expert Rev Pharmacoecon Outcomes Res. 2005 Dec; 5(6):751-61.Expert Rev Pharmacoecon Outcomes Res2005-12-01T00:00:002005Adding clopidogrel to aspirin improves outcome in ST-elevation myocardial infarction patients receiving fibrinolytic therapy.19935784Becker RC, Scheiman J, Dauerman HL, Spencer F, Rao S, Sabatine M, Johnson DA, Chan F, Abraham NS, Quigley EMThe American journal of gastroenterologyManagement of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Am J Gastroenterol. 2009 Dec; 104(12):2903-17.Am J Gastroenterol2009-11-24T00:00:002009Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.18082504Gibson CM, Murphy SA, Pride YB, Kirtane AJ, Aroesty JM, Stein EB, Ciaglo LN, Southard MC, Sabatine MS, Cannon CP, Braunwald EAmerican heart journalEffects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J. 2008 Jan; 155(1):133-9.Am Heart J2007-11-19T00:00:002007Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.18721511Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald EThe American journal of cardiologyOutcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol. 2008 Sep 01; 102(5):552-8.Am J Cardiol2008-06-12T00:00:002008Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).22766336O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Swahn E, Windhausen F, Sabatine MSJournal of the American College of CardiologyAn invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol. 2012 Jul 10; 60(2):106-11.J Am Coll Cardiol2012-07-10T00:00:002012An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.Authorship 10231561329084737Cavallari I, Morrow DA, Creager MA, Olin J, Bhatt DL, Steg PG, Storey RF, Cohen M, Scirica BS, Piazza G, Goodrich EL, Braunwald E, Sabatine MS, Bonaca MPCirculationFrequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. Circulation. 2018 02 13; 137(7):684-692.Circulation2017-10-30T00:00:002017Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.Morrow DA, Wiviott SD, Sabatine MS, Giugliano RP, McCabe CH, Antman EM, Braunwald E.J Am Coll Cardiol.Evaluation of the TIMI Risk Index in a multi-continental population of 19,103 patients with STEMI in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol. 2006; 47(Suppl A):223A.2006-01-01T00:00:002006Evaluation of the TIMI Risk Index in a multi-continental population of 19,103 patients with STEMI in the ExTRACT-TIMI 25 trialShah J, Pinto DS, Kirtane AJ, Bhandiwad A, Murphy SA, Scirica B, Stein E, Nguyen M, Morrow D, Sabatine MS, de Lemos J, Gibson CM.CirculationElectrocardiographic localization of the infarct-related artery in inferior myocardial infarction. Circulation. 2005; 112(Suppl II):II-486.2005-11-02T00:00:002005Electrocardiographic localization of the infarct-related artery in inferior myocardial infarction14769678Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald ECirculationDifferential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.Circulation2004-02-10T00:00:002004Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.Authorship 10255221229117276Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MSJAMA cardiologyClinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cardiol. 2017 12 01; 2(12):1385-1391.JAMA Cardiol2017-12-01T00:00:002017Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.15769761Sabatine MS, Blake GJ, Drazner MH, Morrow DA, Scirica BM, Murphy SA, McCabe CH, Weintraub WS, Gibson CM, Cannon CPCirculationInfluence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005 Mar 15; 111(10):1217-24.Circulation2005-03-15T00:00:002005Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment.17372173Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald ECirculationPrognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007 Mar 27; 115(12):1528-36.Circulation2007-03-19T00:00:002007Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.18082488Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DIAmerican heart journalMyeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008 Jan; 155(1):49-55.Am Heart J2007-11-01T00:00:002007Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.Authorship 10262501529133605Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MSCirculationLow-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation. 2018 01 23; 137(4):338-350.Circulation2017-11-13T00:00:002017Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).11524055Sabatine MS, Januzzi JL, Snapinn S, Théroux P, Jang IKThe American journal of cardiologyA risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris. Am J Cardiol. 2001 Sep 01; 88(5):488-92.Am J Cardiol2001-09-01T00:00:002001A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.Authorship 1029463229141161Giugliano RP, Sabatine MS, Ott BRThe New England journal of medicineCognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 11 16; 377(20):1997.N Engl J Med2017-11-16T00:00:002017Cognitive Function in a Randomized Trial of Evolocumab.22155998Sabatine MSCirculationCardiology patient page. Randomized, controlled trials. Circulation. 2011 Dec 13; 124(24):e832-4.Circulation2011-12-13T00:00:002011Cardiology patient page. Randomized, controlled trials.16291601Sabatine MS, Morrow DA, Montalescot G, Dellborg M, Leiva-Pons JL, Keltai M, Murphy SA, McCabe CH, Gibson CM, Cannon CP, Antman EM, Braunwald ECirculationAngiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005 Dec 20; 112(25):3846-54.Circulation2005-11-15T00:00:002005Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.16505179Armstrong EJ, Morrow DA, Sabatine MSCirculationInflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation. 2006 Feb 28; 113(8):e289-92.Circulation2006-02-28T00:00:002006Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors.17766330Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia JArteriosclerosis, thrombosis, and vascular biologyPrognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007 Nov; 27(11):2463-9.Arterioscler Thromb Vasc Biol2007-08-31T00:00:002007Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.18174457Sabatine MS, Ploughman L, Simonsen KL, Iakoubova OA, Kirchgessner TG, Ranade K, Tsuchihashi Z, Zerba KE, Long DU, Tong CH, Packard CJ, Pfeffer MA, Devlin JJ, Shepherd J, Campos H, Sacks FM, Braunwald EArteriosclerosis, thrombosis, and vascular biologyAssociation between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):562-7.Arterioscler Thromb Vasc Biol2008-01-03T00:00:002008Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.18346960O'Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, Sabatine MSEuropean heart journalAssociation between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J. 2008 Apr; 29(8):984-91.Eur Heart J2008-03-16T00:00:002008Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy.22373720Røysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DAHeart (British Cardiac Society)Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart. 2012 May; 98(10):786-91.Heart2012-02-28T00:00:002012Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.22763456Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, Iwamoto Y, Thompson B, Carlson AL, Heidt T, Majmudar MD, Lasitschka F, Etzrodt M, Waterman P, Waring MT, Chicoine AT, van der Laan AM, Niessen HW, Piek JJ, Rubin BB, Butany J, Stone JR, Katus HA, Murphy SA, Morrow DA, Sabatine MS, Vinegoni C, Moskowitz MA, Pittet MJ, Libby P, Lin CP, Swirski FK, Weissleder R, Nahrendorf MNatureMyocardial infarction accelerates atherosclerosis. Nature. 2012 Jul 19; 487(7407):325-9.Nature2012-07-19T00:00:002012Myocardial infarction accelerates atherosclerosis.O’Donoghue M, Sabatine MS, Cannon CP, Morrow DA, Murphy SA, McCabe CH, Gibson CM.CirculationBaseline neutrophil count is predictive of angiographic outcomes and mortality in patients with STEMI undergoing fibrinolysis: A CLARITY-TIMI 28 substudy. Circulation. 2005; 112(Suppl II):II-486.2005-11-04T00:00:002005Baseline neutrophil count is predictive of angiographic outcomes and mortality in patients with STEMI undergoing fibrinolysis: A CLARITY-TIMI 28 substudyAhmed S, Sabatine MS, Cannon CP, Murphy SA, Braunwald E, Gibson CM.J Am Coll Cardiol.Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28. J Am Coll Cardiol. 2006; 47(Suppl A):159A.2006-01-01T00:00:002006Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis in CLARITY-TIMI 28Johannsen EC, Sabatine MSPharmCardsPharmCards. 2002.2002-01-01T00:00:002002PharmCardsSabatine MS, Colucci WS, Schoen FJZipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine.Primary tumors of the heart. Zipes DP, Libby P, Bonow RO, Braunwald E, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 2005; 1741-56.2005-01-01T00:00:002005Primary tumors of the heartSabatine MS, Cannon CPAcute Coronary Syndromes.Recent advances with clopidogrel in acute coronary syndromes. Acute Coronary Syndromes. 2005; 7:42-6.2005-01-01T00:00:002005Recent advances with clopidogrel in acute coronary syndromes22932716Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DALancet (London, England)Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012 Oct 13; 380(9850):1317-24.Lancet2012-08-26T00:00:002012Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.23131034Mogabgab O, Giugliano RP, Sabatine MS, Cannon CP, Mohanavelu S, Wiviott SD, Antman EM, Braunwald EChronobiology internationalCircadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.Chronobiol Int2012-11-06T00:00:002012Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction.23141813Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MSLancet (London, England)Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012 Dec 08; 380(9858):2007-17.Lancet2012-11-06T00:00:002012Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.Ray KK, Cannon CP, Cairns R, Wiviott SD, Kirtane AJ, Sabatine MS, McCabe CH, Braunwald E, Gibson CM.J Am Coll CardiolBeyond LDL Control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI-22. J Am Coll Cardiol. 2005; 45(Suppl A):332A.2005-03-03T00:00:002005Beyond LDL Control: Additional benefits of better control of hypertension and glycemia in patients on statin therapy: An analysis from PROVE IT-TIMI-22Sabatine MS, Jang I-KCannon CP, ed. The Management of Acute Coronary Syndromes.Antiplatelet and anticoagulant therapy. Cannon CP, ed. The Management of Acute Coronary Syndromes. 2003; 333-75.2003-01-03T00:00:002003Antiplatelet and anticoagulant therapy17631211Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald EJournal of the American College of CardiologyPrognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007 Jul 17; 50(3):205-14.J Am Coll Cardiol2007-06-29T00:00:002007Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.18565400Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MSJournal of the American College of CardiologyThrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008 Jun 24; 51(25):2422-9.J Am Coll Cardiol2008-06-24T00:00:002008Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.Authorship 1034244129273161Sabatine MS, Leiter LA, Wiviott SDThe lancet. Diabetes & endocrinologyQuestioning the safety and benefits of evolocumab - Authors' reply. Lancet Diabetes Endocrinol. 2018 01; 6(1):11-12.Lancet Diabetes Endocrinol2018-01-01T00:00:002018Questioning the safety and benefits of evolocumab - Authors' reply.18456800Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LBAmerican journal of physiology. Lung cellular and molecular physiologyChallenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol. 2008 Jul; 295(1):L16-22.Am J Physiol Lung Cell Mol Physiol2008-05-02T00:00:002008Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs.19358940Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MSJournal of the American College of CardiologyInteraction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol. 2009 Apr 14; 53(15):1273-8.J Am Coll Cardiol2009-04-14T00:00:002009Interaction between cigarette smoking and clinical benefit of clopidogrel.21183500Scirica BM, Sabatine MS, Jarolim P, Murphy SA, de Lemos JL, Braunwald E, Morrow DAEuropean heart journalAssessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011 Mar; 32(6):697-705.Eur Heart J2010-12-22T00:00:002010Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial.21784767O'Donoghue ML, Mallat Z, Morrow DA, Benessiano J, Sloan S, Omland T, Solomon SD, Braunwald E, Tedgui A, Sabatine MSClinical chemistryPrognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem. 2011 Sep; 57(9):1311-7.Clin Chem2011-07-22T00:00:002011Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.22325160Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, Lanktree MB, Tare A, Castillo BA, Li YR, Johnson T, Bruinenberg M, Gilbert-Diamond D, Rajagopalan R, Voight BF, Balasubramanyam A, Barnard J, Bauer F, Baumert J, Bhangale T, Böhm BO, Braund PS, Burton PR, Chandrupatla HR, Clarke R, Cooper-DeHoff RM, Crook ED, Davey-Smith G, Day IN, de Boer A, de Groot MC, Drenos F, Ferguson J, Fox CS, Furlong CE, Gibson Q, Gieger C, Gilhuijs-Pederson LA, Glessner JT, Goel A, Gong Y, Grant SF, Grobbee DE, Hastie C, Humphries SE, Kim CE, Kivimaki M, Kleber M, Meisinger C, Kumari M, Langaee TY, Lawlor DA, Li M, Lobmeyer MT, Maitland-van der Zee AH, Meijs MF, Molony CM, Morrow DA, Murugesan G, Musani SK, Nelson CP, Newhouse SJ, O'Connell JR, Padmanabhan S, Palmen J, Patel SR, Pepine CJ, Pettinger M, Price TS, Rafelt S, Ranchalis J, Rasheed A, Rosenthal E, Ruczinski I, Shah S, Shen H, Silbernagel G, Smith EN, Spijkerman AW, Stanton A, Steffes MW, Thorand B, Trip M, van der Harst P, van der A DL, van Iperen EP, van Setten J, van Vliet-Ostaptchouk JV, Verweij N, Wolffenbuttel BH, Young T, Zafarmand MH, Zmuda JM, Boehnke M, Altshuler D, McCarthy M, Kao WH, Pankow JS, Cappola TP, Sever P, Poulter N, Caulfield M, Dominiczak A, Shields DC, Bhatt DL, Bhatt D, Zhang L, Curtis SP, Danesh J, Casas JP, van der Schouw YT, Onland-Moret NC, Doevendans PA, Dorn GW, Farrall M, FitzGerald GA, Hamsten A, Hegele R, Hingorani AD, Hofker MH, Huggins GS, Illig T, Jarvik GP, Johnson JA, Klungel OH, Knowler WC, Koenig W, März W, Meigs JB, Melander O, Munroe PB, Mitchell BD, Bielinski SJ, Rader DJ, Reilly MP, Rich SS, Rotter JI, Saleheen D, Samani NJ, Schadt EE, Shuldiner AR, Silverstein R, Kottke-Marchant K, Talmud PJ, Watkins H, Asselbergs FW, Asselbergs F, de Bakker PI, McCaffery J, Wijmenga C, Sabatine MS, Wilson JG, Reiner A, Bowden DW, Hakonarson H, Siscovick DS, Keating BJAmerican journal of human geneticsLarge-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet. 2012 Mar 09; 90(3):410-25.Am J Hum Genet2012-02-09T00:00:002012Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci.22813612Bonaca MP, Scirica BM, Sabatine MS, Jarolim P, Murphy SA, Chamberlin JS, Rhodes DW, Southwick PC, Braunwald E, Morrow DAJournal of the American College of CardiologyProspective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2012 Jul 24; 60(4):332-8.J Am Coll Cardiol2012-07-24T00:00:002012Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes.23194481Steg PG, Mehta SR, Pollack CV, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MSAmerican heart journalDesign and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J. 2012 Dec; 164(6):817-24.e13.Am Heart J2012-11-07T00:00:002012Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.Authorship 1036138829301623Magnuson EA, Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Braunwald E, Sabatine MS, Cohen DJJournal of the American College of CardiologyReply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. J Am Coll Cardiol. 2018 01 02; 71(1):108.J Am Coll Cardiol2018-01-02T00:00:002018Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups.Sabatine MSMorrow DA, editor. Cardiovascular Biomarkers: Pathophysiology and Disease Management.Genetic markers in cardiovascular disease. Morrow DA, editor. Cardiovascular Biomarkers: Pathophysiology and Disease Management. 2006; 587-608.2006-01-01T00:00:002006Genetic markers in cardiovascular diseaseSabatine MSEur Heart JClopidogrel in ST-elevation myocardial infarction. Eur Heart J. 2006; 8(Suppl G):G31-G34.2006-01-01T00:00:002006Clopidogrel in ST-elevation myocardial infarctionGupta A, Sabatine MS, Lilly LSLilly LS, ed. Pathophysiology of Heart Disease.Ischemic heart disease. Lilly LS, ed. Pathophysiology of Heart Disease. 2003; 131-56.2003-01-01T00:00:002003Ischemic heart disease19660597Pride YB, Appelbaum E, Lord EE, Sloan S, Cannon CP, Sabatine MS, Gibson CMThe American journal of cardiologyRelation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. Am J Cardiol. 2009 Aug 15; 104(4):475-9.Am J Cardiol2009-06-17T00:00:002009Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction.19699861Wilson SR, Sabatine MS, Braunwald E, Sloan S, Murphy SA, Morrow DAAmerican heart journalDetection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J. 2009 Sep; 158(3):386-91.Am Heart J2009-07-15T00:00:002009Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial.19717184Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald ELancet (London, England)Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009 Sep 05; 374(9692):787-95.Lancet2009-08-28T00:00:002009Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.19942393Becker RC, Scheiman J, Dauerman HL, Spencer F, Rao S, Sabatine M, Johnson DA, Chan F, Abraham NS, Quigley EMJournal of the American College of CardiologyManagement of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol. 2009 Dec 08; 54(24):2261-76.J Am Coll Cardiol2009-12-08T00:00:002009Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.Authorship 103799514Authorship 1037752229327884Giugliano RP, Sabatine MS, Ott BRThe New England journal of medicineCognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017 Nov 16; 377(20):1997.N Engl J Med2017-11-16T00:00:002017Cognitive Function in a Randomized Trial of Evolocumab.29322605Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SDDiabetes, obesity & metabolismDECLARE-TIMI 58: Participants' baseline characteristics. Diabetes Obes Metab. 2018 05; 20(5):1102-1110.Diabetes Obes Metab2018-02-14T00:00:002018DECLARE-TIMI 58: Participants' baseline characteristics.22446996Bui AH, Bonaca MP, Sabatine MS, Ray KK, Rifai N, Cannon CP, Morrow DAJournal of thrombosis and thrombolysisElevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis. 2012 Aug; 34(2):222-8.J Thromb Thrombolysis2012-08-01T00:00:002012Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.23520015Mogabgab O, Wiviott SD, Antman EM, Foody JM, Wang TY, Sabatine MS, Cannon CP, Li S, Giugliano RPClinical cardiologyRelation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.Clin Cardiol2013-03-20T00:00:002013Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry.Scirica BM, Sabatine MS, Cannon CP, McCabe CH, Braunwald E, Stone PH.J Am Coll Cardiol.Clopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY-TIMI 28. J Am Coll Cardiol. 2006; 47(Suppl A):213A.2006-01-01T00:00:002006Clopidogrel attenuates the complications associated with poor early reperfusion in patients with STEMI undergoing lysis in the CLARITY-TIMI 28Sabatine MS, editor.Pocket MedicinePocket Medicine. 2004.2004-01-01T00:00:002004Pocket MedicineScirica BM, Sabatine MS, Murphy SA, Kirtane A, Aroesty J, Cannon CP, Gibson CM.CirculationImproved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST Elevation Myocardial Infarction - Results From CLARITY-TIMI 28. Circulation. 2005; 112(Suppl II):II-693.2005-11-07T00:00:002005Improved findings on late angiography are associated with lower rates of new Q-waves in patients receiving fibrinolysis for ST Elevation Myocardial Infarction - Results From CLARITY-TIMI 2817560290Sabatine MS, Morrow DA, Dalby A, Pfisterer M, Duris T, Lopez-Sendon J, Murphy SA, Gao R, Antman EM, Braunwald EJournal of the American College of CardiologyEfficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol. 2007 Jun 12; 49(23):2256-63.J Am Coll Cardiol2007-05-25T00:00:002007Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.18769631Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten REThe Journal of clinical investigationMetabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008 Oct; 118(10):3503-12.J Clin Invest2008-10-01T00:00:002008Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury.18997177Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald EEuropean heart journalDetection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J. 2009 Jan; 30(2):162-9.Eur Heart J2008-11-08T00:00:002008Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35.20022985Gerszten RE, Carr SA, Sabatine MClinical chemistryIntegration of proteomic-based tools for improved biomarkers of myocardial injury. Clin Chem. 2010 Feb; 56(2):194-201.Clin Chem2009-12-18T00:00:002009Integration of proteomic-based tools for improved biomarkers of myocardial injury.21318582Ahmed S, Michael Gibson C, Cannon CP, Murphy SA, Sabatine MSJournal of thrombosis and thrombolysisImpact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis. J Thromb Thrombolysis. 2011 May; 31(4):493-500.J Thromb Thrombolysis2011-05-01T00:00:002011Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.15117853Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RTCirculationSerum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004 May 11; 109(18):2186-90.Circulation2004-04-26T00:00:002004Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction.15653022Sabatine MS, Braunwald EJournal of the American College of CardiologyAnother look at the age-old question: which came first, the elevated c-reactive protein or the atherothrombosis? J Am Coll Cardiol. 2005 Jan 18; 45(2):244-5.J Am Coll Cardiol2005-01-18T00:00:002005Another look at the age-old question: which came first, the elevated c-reactive protein or the atherothrombosis?22446997Vora AN, Bonaca MP, Ruff CT, Jarolim P, Murphy S, Croce K, Sabatine MS, Simon DI, Morrow DAJournal of thrombosis and thrombolysisDiagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain. J Thromb Thrombolysis. 2012 Aug; 34(2):229-34.J Thromb Thrombolysis2012-08-01T00:00:002012Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain.22496256Mega JL, Topol EJ, Sabatine MSJAMACYP2C19 genotype and cardiovascular events. JAMA. 2012 Apr 11; 307(14):1482-3; author reply 1484-5.JAMA2012-04-11T00:00:002012CYP2C19 genotype and cardiovascular events.O’Donoghue M, Sabatine MS, Wiviott SD, Murphy SA, McCabe CH, Cannon CP, Braunwald E, Gibson CM.J Am Coll Cardiol.Association of TIMI Risk Score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY-TIMI 28 Substudy. J Am Coll Cardiol. 2006; 47(Suppl A):222A.2006-01-01T00:00:002006Association of TIMI Risk Score and extent of coronary artery disease in patients with ST-elevation myocardial infarction: A CLARITY-TIMI 28 SubstudySabatine MS, Morrow DA, Antman EMTheroux P, ed. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease.Risk Stratification in Unstable Angina/Non-ST Elevation Myocardial Infarction. Theroux P, ed. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. 2003; 308-21.2003-06-06T00:00:002003Risk Stratification in Unstable Angina/Non-ST Elevation Myocardial Infarction12075250Sabatine MS, McCabe CH, Morrow DA, Giugliano RP, de Lemos JA, Cohen M, Antman EM, Braunwald EAmerican heart journalIdentification of patients at high risk for death and cardiac ischemic events after hospital discharge. Am Heart J. 2002 Jun; 143(6):966-70.Am Heart J2002-06-01T00:00:002002Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.